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7Tiivistelmä, Finnish summary
Fosforin saanti on länsimaissa kaksin-kolminkertaista suhteessa
ravitsemussuosituksiin. Fosforin kokonaissaantia on kasvattanut
fosforilisäaineiden käyttö elintarviketeollisuudessa ja on arvioitu, että jopa 10-
50 prosenttia fosforin saannista on peräisin lisäaineista.
Elintarvikekoostumustietokannoissa reseptipohjaisten elintarvikkeiden
fosforipitoisuudet on laskettu raaka-aineiden pitoisuuksien perusteella, jolloin
ne eivät perustu kemiallisesti analysoituihin tietoihin. Tällöin lisäaineiden
osuutta fosforipitoisuuksissa ei välttämättä ole otettu huomioon. Fosforin
todellisen saannin arviointia vaikeuttaa myös fosforin hyväksikäytettävyyden
vaihtelevuus eri fosforilähteiden välillä; lisäaineperäinen epäorgaaninen fosfori
imeytyy elimistöön paremmin kuin elintarvikkeen luontainen, orgaaninen
fosfori. Munuaistautipotilailla runsaan fosforin saannin haitallisuus on ollut
tiedossa jo pitkään, ja fosforirajoitteista ruokavaliota käytetään osana heidän
hoitoaan, jotta mm. verisuonten kalkkeutumista voitaisiin estää;
kalkkeutumisessa kalsiumfosfaattia saostuu suonten seinämiin. Viime vuosina
on saatu tutkimustuloksia seerumin kohonneen fosfaattipitoisuuden
haittavaikutuksista sydän- ja verisuonitautien riskiin ja verisuonten
kalkkeutumiseen myös terveellä väestöllä, mutta ravinnon fosforin osalta
tutkimustietoa on niukasti. Tämän väitöskirjatyön tavoitteena on valottaa
runsaan fosforin saannin mahdollisia terveysriskejä Suomessa tuottamalla tietoa
elintarvikkeiden fosforin hyväksikäytettävyydestä ja runsaan fosforin saannin
yhteyksistä sydän- ja verisuonitautien riskitekijöihin väestötasolla.
Väitöskirjan ensimmäisessä osatyössä kehitettiin in vitro -analyysimenetelmä
liukoisen, ns. elimistöön imeytyvän ja hyväksikäytettävissä olevan, fosforin
pitoisuuksien määrittämiseen elintarvikkeista sekä analysoitiin liukoisen ja
kokonaisfosforin määriä eri tavoin käsitellyistä ruis-, vehnä- ja ohranäytteistä.
Hypoteesina oli, että viljatuotteiden prosessointi lisää liukoisen fosforin määrää.
Analyysimenetelmästä johtuva laskennallinen epävarmuus vaikutti liukoisen
fosforin pitoisuuksiin näytteissä suhteellisen vähän. Hapatetuissa viljatuotteissa
liukoisen fosforin määrä oli suurempi kuin hapattamattomissa, myös pitkä
kypsennysaika lisäsi liukoisen fosforin pitoisuuksia. Tämä johtunee viljojen
8sisältämän fosforipitoisen fytaatin pilkkoutumisesta käsittelyn aikana, jolloin
siitä vapautuu liukoista, epäorgaanista fosforia.
Toisessa osatyössä hyödynnettiin ensimmäisessä osatyössä kehitettyä
menetelmää liukoisen fosforin pitoisuuksien määrittämiseen valikoiduista
kasvipohjaisista elintarvikkeista ja juomista. Myös kokonaisfosforipitoisuudet
määritettiin ja liukoisen fosforin pitoisuuksia verrattiin niihin. Hypoteesina oli,
että lisäainefosforia sisältävissä tuotteissa liukoisen fosforin osuudet ovat
suhteellisesti korkeampia kuin tavanomaisissa tuotteissa. Tutkimuksessa
havaittiin, että analysoidut kasvipohjaiset elintarvikkeet sisälsivät vaihtelevia
määriä fosforia, mutta suurin osa siitä ei ollut liukoista lukuun ottamatta
lisäainefosforia sisältäviä tuotteita. Lisäainefosforia sisältävissä tuotteissa,
kuten kolajuomissa ja leivinjauheella kohotetuissa muffinseissa, oli suurempi
liukoisen fosforin osuus verrattuna tavanomaisiin tuotteisiin.
Kolmannessa osatyössä tutkittiin poikkileikkausasetelmalla keski-ikäisillä
miehillä ja vaihdevuosi-ikää edeltävillä naisilla fosforin kokonaissaannin,
ravinnon fosforitiheyden (fosforin saanti suhteutettuna energian saantiin) sekä
lisäainefosforin saannin yhteyksiä sydän- ja verisuonitautien riskitekijään,
kaulavaltimon seinämän paksuuteen (n=546). Lisäainefosforin saantia tutkittiin
ruoankäytön frekvenssikyselylomakkeella, muut ruoankäyttötiedot kerättiin
kolmen vuorokauden ruokapäiväkirjanpidolla. Hypoteesina oli, että runsas
fosforin saanti, etenkin lisäainefosforin muodossa, on yhteydessä verisuonten
kalkkeutumista kuvaavaan paksumpaan kaulavaltimon seinämään ja täten
suurentuneeseen sydän- ja verisuonitautien riskiin. Tutkimuksessa havaittiin
lineaarinen yhteys ravinnon fosforitiheyden ja lisäainefosforin saannin sekä
kaulavaltimon seinämän paksuuden välillä koko aineistossa, ja naisilla
lisäainefosforin saannin ja kaulavaltimon seinämän paksuuden välillä. Miehillä
tilastollisesti merkitseviä tuloksia ei ollut havaittavissa. Tulosten perusteella
runsas fosforin saanti, etenkin lisäainefosforin muodossa, saattaisi olla yksi
sydän- ja verisuonitautien riskitekijöistä myös väestötasolla, ei ainoastaan
munuaistautipotilailla.
Väitöskirjan tulokset tukevat aiempaa käsitystä siitä, että fosforilähteellä on
merkitystä arvioitaessa fosforin saantia väestötasolla. Kasvikunnan tuotteet
9yleisesti sisältävät vähäisiä määriä liukoista fosforia mutta
lisäainefosforipitoiset kasvipohjaiset elintarvikkeet sisältävät suhteellisesti
suurempia liukoisen fosforin pitoisuuksia verrattuna tavanomaisiin tuotteisiin.
Tulosten perusteella liukoisen fosforin määritysmenetelmä elintarvikkeista on
luotettava mutta tarvitsee vertailuarviointia in vivo -analyysimenetelmän kanssa
ennen kuin tuloksia voidaan yleistää. Vaikka runsaan fosforin saannin
(ravinnon fosforitiheys ja lisäainefosforin saanti) havaittiin olevan yhteydessä
yhteen sydän- ja verisuonitautien riskitekijään, kaulavaltimon seinämän
paksuuteen, poikkileikkaustutkimusasetelman perusteella syy-seuraussuhteita ei
kuitenkaan voida päätellä. Tämän vuoksi etenkin hyvin imeytyvän
lisäainefosforin mahdollisia haittavaikutuksia sydän- ja verisuoniterveyteen
pitäisi tutkia tarkemmin sekä interventio- että seurantatutkimuksilla ennen kuin
runsaan fosforin saannin mahdollisesta haitallisuudesta väestötasolla voidaan
tehdä lopullisia johtopäätöksiä. Tämän selvittämiseksi tarvitaan lisää tietoa
myös fosforilisäaineiden käytöstä elintarviketeollisuudessa sekä päivitettyjä
analyysitietoja elintarvikkeiden fosforipitoisuuksista.
AVAINSANAT: elintarvikelisäaineet, elintarvikkeet, fosfaatti, fosfori,
hyväksikäytettävyys, kasvipohjaiset elintarvikkeet, kaulavaltimon seinämän
paksuus, liukoinen fosfori, sydän- ja verisuonitaudit, verisuonten
kalkkeutuminen, viljatuotteet
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Abstract
Phosphorus (P) intake in Western countries exceeds the nutritional
recommendations 2- to 3-fold, and the increased use of food additive
phosphates  (FAPs)  in  the  food  industry  has  augmented  total  P  (TP)  intake;  an
estimated 10-50% of TP intake comes from additives. Difficulties in measuring
true P intake occur because bioavailability of P differs between foodstuffs;
inorganic P from additives is absorbed better in the intestine than natural,
organic P. Moreover, in food composition databases, P contents of the recipe-
based foodstuffs are calculated based on nutrient contents of raw materials, and
not on chemically analyzed values. Thus, the amounts of FAPs may have not
been taken into account. It has been stated that all P sources cannot be defined
similarly as detrimental to health due to differing absorbability and
bioavailability.  The  harmfulness  of  high  P  intake  to  kidney  patients  has  been
known for years, and dietary P restriction is used in the treatment of the disease,
to avoid vascular calcification, which occurs due to calcium-phosphate
deposition in the vascular vessel wall. However, recently, concerns have been
raised about the role of elevated serum phosphate concentrations in
cardiovascular health in the general population, but data on dietary P is scarce.
This thesis aims to offer new insights into the potential health risks related to
high dietary P intake in Finland by providing knowledge on the bioavailability
of  P  in  foodstuffs,  and  on  the  association  of  high  dietary  P  intake  with
cardiovascular disease risk factors in the general population.
In  Study  I,  a  new  method  was  developed  for  analysis  of in vitro digestible P
(DP), indicating bioavailable and absorbable P, and in vitro DP and TP contents
of certain differently processed rye, wheat and barley samples were detetrmined.
The hypothesis was that processing of cereals increases the content of DP.  The
calculated uncertainty of the analysis method had little effect on the DP
contents in the samples. Soured cereals contained more DP than unsoured
cereals, and the long processing time increased the amounts of DP. This
probably is due to the degradation of P-containing phytate, which releases
digestible, inorganic P.
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In Study II, the DP contents of selected plant-based foodstuffs and beverages
were determined by the analysis method developed in Study I. Also TP contents
were analyzed, and DP contents in the same foods were compared to them. The
hypothesis was that the proportion of DP is lower in plant-based FAP-free
products than in products containing FAPs. The analyzed plant-based products
contained varying amounts of P, but most P was not absorbable, except in FAP-
containing foodstuffs. The FAP-containing products, especially cola drinks and
baking powder-leavened muffins, had higher amounts of DP relative to FAP-
free products.
In Study III, a cross-sectional design was used to investigate the associations
between TP intake, P density of the diet (TP intake related to energy intake),
FAP intake, and a risk factor of cardiovascular disease, carotid intima-media
thickness in middle-aged males and premenopausal females (n=546).  Data on
FAP intake were collected by food frequency questionnaires, and nutrients
other than FAP were assessed by 3-day food records. Hypothesis was that high
dietary P intake, especially in the form of FAP, is associated with vascular
calcification in terms of high carotid intima-media thickness and thus, with
increased risk of cardiovascular diseases. Here, linear associations among P
density of the diet, FAP intake, and carotid intima-media thickness were found
when all subjects were included in the analysis, and between FAP intake and
carotid intima-media thickness in females. However, among males no
significant associations were found. These findings suggest that high dietary P
intake, especially in the form of FAP, could be a cardiovascular risk factor not
only in renal patients but also in the general population.
In conclusion, results of this thesis reinforce the previous understanding about
the importance of the source of P when assessing P intake in a population. The
plant-based foodstuffs generally contain low amounts of absorbable P, but the
FAP-containing plant-based products have relatively higher absorbable P
contents than FAP-free products. The method developed for the analysis of DP
is reliable but requires validation against an in vivo method before these results
can be generalized. Albeit high dietary P intake (P density of the diet and FAP
intake) was associated with a cardiovascular disease risk factor, carotid intima-
media thickness, due to the cross-sectional design of the study, no causal
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relationships can be inferred. Thus, the potential adverse effects of highly
absorbable FAPs should be further investigated both in intervention and in
follow-up  studies  before  final  conclusions  about  the  harmfulness  of  high  P
intake for the general population can be drawn. To find this out, data on use of
FAPs in the food industry and updated information on P contents in foodstuffs
are also needed.
KEY WORDS: bioavailability, cardiovascular diseases, carotid intima-media
thickness, cereals, digestible phosphorus, food additives, foodstuffs, phosphate,
phosphorus, plant-based foodstuffs, vascular calcification
13
List of original publications
This thesis is based on the following publications, referred to in the text by their
Roman numerals (I-III):
I: Itkonen ST,  Ekholm  PJ,  Kemi  VE,  Lamberg-Allardt  CJE.  Analysis  of  in
vitro digestible phosphorus content in selected processed rye, wheat and barley
products. J Food Comp Anal 2012;25:185-189.
II:  Karp  H,  Ekholm  P,  Kemi  V, Itkonen S,  Hirvonen  T,  Närkki  S,  Lamberg-
Allardt C. Differences among total and in vitro digestible phosphorus content of
plant foods and beverages.  J Ren Nutr 2012;22:416-422.
III: Itkonen ST, Karp HJ, Kemi VE, Kokkonen EM, Saarnio EM, Pekkinen MH,
Kärkkäinen MUM, Laitinen EKA, Turanlahti MI, Lamberg-Allardt CJE.
Associations among total and food additive phosphorus intake and carotid
intima-media thickness – A cross-sectional study in a middle-aged population
in Southern Finland. Nutr J 2013;12:94.
These publications have been reprinted with the kind permission of their
copyright holders. In addition, some unpublished results are presented.
Contribution of the authors to Studies I-III
I: PJE designed the analyses and STI performed the sampling. STI conducted the P
analyses. STI analyzed and interpreted the data. STI drafted the manuscript with the
help of PJE. All authors read, reviewed and approved the final manuscript.
II:  HK,  PE,  VK,  TH  and  CLA  planned  the  study.  SN  carried  out  the  laboratory
analysis. HK, PE, and SI analyzed the data. HK wrote the manuscript with PE and TH,
and SI and the other co-authors critically reviewed the paper.
III:  STI,  HJK,  VEK,  and  CJELA  designed  the  study.  MIT  designed  the  IMT
measurement.  STI,  HJK,  VEK,  EMS,  MHP,  and  MUMK collected  the  data.  STI  and
EMK analyzed the data.  STI,  CJELA, and EMK interpreted the data.  STI drafted the
manuscript with the help of CJELA. STI, EMK, and CJELA are responsible for the
integrity of data analysis. All authors read, reviewed and approved the final manuscript.
14
Abbreviations
1,25(OH)2D 1,25-hydroxy vitamin D, calcitriol
25(OH)D 25-hydroxy vitamin D, calcidiol
ANCOVA analysis of covariance
ANOVA analysis of variance
BMI body mass index
Ca calcium
CaPi calcium-phosphate
cIMT carotid intima-media thickness
CKD chronic kidney disease
CRP C-reactive protein
C-terminal FGF23 carboxy-terminal fibroblast growth factor 23
CV% coefficient of variation percentage
CVD cardiovascular disease
CYP2R1 cytochrome P 450 2R1
CYP24A1 cytochrome P 450 24A1
CYP27B1 cytochrome P 450 27B1
DP digestible phosphorus
EFSA European Food Safety Authority
eGFR estimated glomerulus filtration rate
FAP food additive phosphate
FFQ food frequency questionnaire
FGF23 fibroblast growth factor 23
GFR glomerulus filtration rate
HDL high-density lipoprotein
HDL-C high-density lipoprotein cholesterol
HNO3 nitric acid
hs-CRP high-sensitivity C-reactive protein
iCa ionized calcium
iPTH intact parathyroid hormone
ICP-AES inductively coupled plasma -atomic emission spectrometry
ICP-MS inductively coupled plasma -mass spectrometer
ICP-OES inductively coupled plasma -optical emission spectrometer
IMT intima-media thickness
LDL low-density lipoprotein
LDL-C low-density lipoprotein cholesterol
Mg magnesium
Na sodium
NaPi 2a sodium-dependent phosphate cotransporter 2a
NaPi 2b sodium-dependent phosphate cotransporter 2b
NaPi 2c sodium-dependent phosphate cotransporter 2c
P phosphorus
Pi phosphate
PTH parathyroid hormone
P-Pi plasma phosphate
S-Pi serum phosphate
TP total phosphorus
15
1. Introduction
The Western population is aging and the incidence of many diseases is on the
rise. Cardiovascular diseases (CVD) are leading causes of mortality and
morbidity worldwide (O’Leary and Bots 2010), and the incidence of renal
disease is also increasing as an adjuvant disease of type 2 diabetes (Niemi and
Winell  2005).  Traditional  risk  factors  for  CVD  are  well  known,  but  concerns
have  recently  been  raised  on  the  role  of  high  dietary  phosphorus  (P)  intake  in
CVD. Especially in patients with chronic kidney disease (CKD), high dietary P
intake has been shown to be deleterious, and high serum phosphate (S-Pi)
concentrations in this patient group are associated with a higher risk of
mortality (Qunibi et al. 2002). CKD patients are unable to excrete P properly,
thus, they are treated with dietary P restriction (Qunibi et al. 2002). Subsequent
research data have revealed associations between high S-Pi concentrations and
higher risk of cardiovascular diseases and mortality also in the general
population (Tonelli et al. 2005, Foley et al. 2009, Ruan et al. 2010).
P  intake  in  Western  countries  exceeds  2-  to  3-fold  (Calvo  1993,  Welch  et  al.
2009, Helldán et al. 2013a, Massé et al. 2014) the nutritional recommendations
(600-700 mg/d) (Food and Nutrition Board 1997, Nordic Council of Ministers
2013). Results on the detrimental effects of high P intake on bone metabolism
have been reported (Kärkkäinen and Lamberg-Allardt 1996, Kemi et al. 2006,
2008, 2009, 2010), but information on high P intake and CVD in the general
population is scarce. Experimental work has shown that high dietary P intake
induces vascular calcification; deposition of calcium-phosphate (CaPi)
complexes in the vascular vessel wall (Uribarri and Calvo 2013). High P intake
has also caused the left ventricular hypertrophy of the heart (Yamamoto et al.
2013) and has acutely impaired the endothelial function of the vascular system
(Shuto et al. 2009). A recent study of the NHANES III population showed that
high P intake was associated with increased all-cause mortality (Chang et al.
2014a).
Dietary P is an important element in energy metabolism, in phosphorylation of
proteins, in maintaining the acid-base equilibrium, and in bone as a component
of hydroxyapatite.  Almost all foodstuffs contain P, but the intake has mainly
16
increased as a consequence of the expanding use of food additive phosphates
(FAP) in the food industry (Suurseppä et al. 2001, Winger et al. 2012).
Carrigan et al. (2014) estimated that 10-50 % of total P (TP) intake in Western
countries comes from FAPs, and intake values of up to 1000 mg/d have been
presented (Winger et al. 2012). Bioavailability of P differs between foodstuffs;
in cereals and legumes P is in the form of phytic acid and thus, not soluble until
degraded in food processing (Sandberg 2002). However, more than 90% of P
from FAPs is absorbed by the human body (Sullivan et al. 2007). When
assessing  P  intake,  some  difficulties  exist:  natural  P  and  FAP  cannot  be
distinguished analytically (Suurseppä et al. 2001); thus, the P contents of
foodstuffs in food composition databases are reported as TP. Moreover, in food
composition databases, P contents of the recipe-based foodstuffs are calculated
based on nutrient contents of raw materials, and not on chemically analyzed
values. Thus, the amounts of FAPs may have not been taken into account
(Oenning et al. 1988, Sullivan et al. 2007).
Thus, a new method is needed to assess in vitro the  digestible  P  (DP)
(corresponding to the bioavailable P) in foodstuffs. Because of raised concerns
on potential adverse health effects of high P intake and elevated S-Pi
concentrations (Tonelli et al. 2005, Kemi et al. 2006, Huttunen et al. 2006, 2007,
Foley et al. 2009, Shuto et al. 2009, Ruan et al. 2010), the scope of this study
was widened to include the normal population and habitual dietary P intake as
TP and FAP. A new analytical method is developed for measurement of the in
vitro DP contents in foodstuffs, and analysis of DP in differently processed
cereals is carried out (Study I), as well as the differences between TP and in
vitro DP content in selected popular P-containing plant-based foodstuffs (Study
II) are examined. Moreover, associations between dietary P and cardiovascular
health in terms of carotid intima-media thickness (IMT) are discussed (Study
III).
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2. Review of the literature
2.1. Phosphorus in human nutrition
2.1.1. Dietary intake and recommendations
The National Nutrition Council recommends a P intake of 600 mg/d for adults
of both sexes (National Nutrition Council 2014), based on Nordic Nutrition
Recommendations (Nordic Council of Ministers 2013) (Table 1). The upper
limit of daily P intake is 5000 mg/d (National Nutrition Council 2014). In the
United States, the estimated average requirement (except for adolescents) is 400
mg/d, and the recommended daily intake is 700 mg/d (Food and Nutrition
Board 1997). The European Food Safety Authority produced a report in 2005
concerning the potential adverse effects of high P intake, but made no
recommendations based on these effects (EFSA 2005).
Table 1. Recommended phosphorus (P) intakes in different age groups 1.
Age Recommendation (P mg/d)
<6 months -
6-11 months 420
12-23 months 470
2-5 years 470
6-9 years 540
10-13 years 700
14-17 years 700
18-20 years 700
Adults >20 years 600
Pregnant women 700
Breastfeeding women 900
1National Nutrition Council 2014
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Dietary P intake in Western countries exceeds 2- to 3-fold (Calvo 1993, Welch
et al. 2009, Helldán 2013a) the nutritional recommendations (600-700 mg/d)
(Food and Nutrition Board 1997, Nordic Council of Ministers 2013). Mean
intake of P in the National FINDIET 2012 Survey was among females 1369
mg/d and among males 1694 mg/d, being lower in the older age groups
(Helldán et al. 2013a). In Finland, the most important sources of P are dairy
products (males 36%, females 35% of P intake), cereal products (males 20%,
females 24%) and meat products (males 17%, females 14%) (Helldán et al.
2013a). Table 2 shows the approximate mean P intake ranges in the European
countries  that  participated  in  the  EPIC  study  (Welch  et  al.  2009).  When
comparing mean dietary P intakes in Finland from 2002 to 2012, the mean
intakes have decreased (males: from 1928 to 1694 mg/d; females from 1465 to
1369 mg/d), however, the different assessment methods (3-day food records vs.
48-h food recalls) may impair the comparability between the results (Kleemola
et al. 1994, Helldán et al. 2013a).
2.1.2. Functions of phosphate in the body
P, in the form of phosphate (Pi), is required in several biological processes in
the human body. Pi participates in the energy metabolism as a component of
Table 2. Approximate ranges of phosphorus (P) intakes stratified by gender in the  EPIC
study in European countries (based on Welch et al. 2009).
Country Females Males
Greece 1500 2100
Spain 1150-1400 1550-1900
Italy 1100-1200 1500-1700
France 1300 -
Germany 1100-1200 1500
The Netherlands 1350-1500 1800
United Kingdom 1200-1300 1400-1600
Denmark 1400-1500 1800
Sweden 1200-1300 1500-1650
Norway 1350 2100
Approximate range of P intake (mg/d)
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adenosine triphosphate, creatinine Pi and other phosphorylated compounds such
as nucleic acids (Knochel 2006). For instance, some hormones need Pi for the
phosphorylation process. Pi exists also as a part of phospholipids in membranes,
it acts as a buffer in acid-base homeostasis on the bone surface and regulates
proton balance in the kidneys (Knochel 2006). An adult human body contains
approximately 700 g P (Gaasbeek and Meinders 2005). Most of this, i.e. 60%,
occurs as hydroxyapatite in the bone. A further 9% is in skeletal muscles, 10.9%
in internal organs, and 0.1% in the extracellular matrix. In blood, Pi occurs in
both organic and inorganic forms. The organic form comprises carbohydrates,
lipids, and proteins. Of inorganic Pi, 85% occurs as free Pi ions (HPO4-2,
H2PO4-1 ja PO4-3),  10% is bound to proteins,  and 5% exists as a component of
calcium- (Ca), magnesium- (Mg) and sodium- (Na) bound compounds
(Gaasbeek and Meinders 2005).
2.1.3. Phosphorus balance
An adult weighing 70 kg gets about 1600 mg P daily from the diet, and of this,
about 40-80 % is absorbed in the intestinal tract, and about 1 g is excreted in the
urine. The kidneys are the main regulator of P balance in the body (Heaney
2004, Bergwitz and Jüppner 2010). Absorption is regulated by parathyroid
hormone (PTH), calcitriol (1,25-hydroxy vitamin D, i.e. 1,25(OH)2D), and
fibroblast growth factor 23 (FGF23), the latter needing Klotho as its co-receptor.
About 30% of P absorption is regulated by 1,25(OH)2D (Bergwitz and Jüppner
2010) and the rest is absorbed in a paracellular fashion. Most of P is absorbed in
the jejunum, where sodium-dependent phosphate cotransporter 2b (NaPi2b)
mediates active intestinal P absorption, and is regulated by 1,25(OH)2D.
Absorbed P is stored in the skeleton (Bergwitz and Jüppner 2010). Figure 1
shows the balance between absorption and excretion of P.
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Figure 1. Phosphorus balance in humans (adapted from Berndt and Kumar
2007).
P homeostasis interfaces with Ca homeostasis in the kidney (Peacock 2010). P
reabsorption  from  urine  in  renal  proximal  tubules  by  type  2  and  3  sodium-
dependent phosphate cotransporters (NaPi2 and NaPi3) is the main factor
maintaining blood Pi homeostasis, and this is regulated by PTH and FGF23
(Bergwitz and Jüppner 2010). Pi is taken up into the cells from the circulation
via these transporters. In addition, some other hormones, such as insulin,
hormones on the somatotrophic pituitary axis, and possibly also fibroblast
growth factor 7, matrix extracellular glycoprotein and secreted frizzled-related
protein-4,  seem to  participate  in  P  homeostasis,  but  their  exact  functions  have
yet to be elucidated (Bergwith and Jüppner 2010). When dietary P intake is
high, FGF23 is secreted from bone to bloodstream. This suppresses secretion
and synthesis of PTH, Pi reabsorption in the kidney, and production of
1,25(OH)2D (Kuro-o 2013). FGF23 works synergistically with PTH to increase
renal Pi excretion by reducing expression of sodium-dependent phosphate
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cotransporters 2a and 2c (NaPi2a and NaPi2c) in the proximal tubules
(Bergwith and Jüppner 2010). PTH, which has receptors in the kidney,
increases renal phosphate clearance and stimulates synthesis of 1,25(OH)2D
(Bergwith and Jüppner 2010).  However, the receptor that senses the S-Pi
concentration has not yet been identified (Peacock 2010). Furthermore, dose
response between S-Pi and FGF23 is much less rapid than, for instance,
between Ca and its regulating hormones (Peacock 2010).
Pi is analyzed from serum or plasma as inorganic phosphate. The normal ranges
for  serum  phosphate  (S-Pi)  concentrations  are  for  females  0.85-1.50  mmol/l
(corresponding to 2.63-4.64 mg/dl), for males ≤50 years of age 0.75-1.65
mmol/l (corresponding to 2.32-5.11 mg/dl), and for males ≥50 years 0.75-1.35
mmol/l (corresponding to 2.32-4.18 mg/dl) (Yhtyneet Medix Laboratoriot
2014). Normal Pi concentrations in children are higher than in adults, gradually
lowering with age.
2.1.4. Regulators of phosphate metabolism
Many regulators participate in the Pi metabolism: PTH, FGF23 and it’s co-
receptor Klotho, 1,25(OH)2D, Ca, secreted frizzled-related protein-4 and matrix
extracellular glycoprotein. It is noteworthy that FGF23 and its contribution to Pi
metabolism were unknown when many of the earlier studies on high P intake
were done (Calvo and Tucker 2013); thus, newer studies have uncovered novel
information on this topic.  Figure 2 presents the regulators of P metabolism and
their interactions.
Serum phosphate and serum calcium
One percent of Pi in the human body is in serum, which is controlled to some
degree by dietary P. Dietary P is known to have an impact on the biphasic
circadian rhythm of S-Pi (Portale et al. 1987, Kärkkäinen and Lamberg-Allardt
1996). Changes in dietary P intake have an effect on the first phase of the
rhythm pattern but independent of diet, the peak in S-Pi concentrations occurs
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in the early morning (Portale et al. 1987). However, dietary P has only a small
impact on S-Pi when measured after fasting or randomly, but increasing P
intake acutely increases S-Pi (Portale et al. 1987, Kemi et al. 2006). Mean 24-h
S-Pi concentrations and peak S-Pi after P load are proposed to be more useful
than fasting S-Pi concentrations when assessing the effects of dietary P intake
(Uribarri 2013). It is notable that in healthy adults and animals a high P diet for
weeks can result in increased FGF23 or PTH without any perceivable changes
in S-Pi (Uribarri and Calvo 2013). Increased Ca intake increases serum ionized
Ca (iCa), which decreases S-PTH, leading to a lower excretion of P in urine
(Mortensen and Charles 1996). Calcium sensing receptor reacts to elevated
concentrations of S-Ca, inducing lowering of S-PTH concentrations. High S-Ca
concentration stimulates FGF23 excretion and suppresses PTH secretion (Silver
and Naveh-Many 2009).
Figure 2. Relationships between dietary phosphorus and regulator of
metabolism. S-Pi = serum phosphate, S-Ca = serum calcium, 1,25(OH)2D  =
23
calcitriol, PTH = parathyroid hormone, FGF-23 = fibroblast growth factor 23
(adapted from Silver and Naveh-Many 2009).
Parathyroid hormone
PTH is secreted from parathyroid glands (Bergwitz and Jüppner 2010). It
regulates S-Pi, and elevated S-Pi stimulates PTH, probably by lowering
extracellular Ca, and increasing stability of PTH messenger RNA. Continuous
exposure to PTH induces bone resorption by activating osteoclasts but
intermittent PTH increases bone formation by activating osteoblasts (Bergwitz
and Jüppner 2010). PTH secretion is regulated by S-Pi and FGF23 and Klotho
in the parathyroid gland. FGF23 is able to inhibit the synthesis of 1,25(OH)2D,
which may negatively affect the secretion of PTH (Bergwith and Jüppner 2010).
However, PTH concentrations have been perceived to increase in response to
increased S-Pi independently of S-Ca (Kärkkäinen and Lamberg-Allardt 1996).
PTH is downregulated by increased S-Ca and 1,25(OH)2D and possibly by
increased FGF23. PTH acts through G protein-coupled receptor PTHR1 to
increase osteoblast activity (and thus, indirectly osteoclast activity) to inhibit
renal  Pi  absorption,  and  to  stimulate  1,25(OH)2D  synthesis,  which  causes  an
increase in S-Ca and a decrease in S-Pi (Bergwith & Jüppner 2010). PTH and
FGF23 work synergistically to increase renal Pi excretion by reducing
expression of NaPi2a and NaPi2c (Bergwitz and Jüppner 2010).
There is circadian variation in S-PTH concentrations, being lowest in the
morning. Sex differences also appear to exist in the rhythm (Calvo et al. 1991).
The rhythm is biphasic, as in S-Pi. PTH responds acutely to high dietary P load
(Block et al. 2013), thus increasing urinary Pi excretion.
Calcitriol, i.e. 1,25-dihydroxy vitamin D
Vitamin D exists as cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2).
The former is produced in the skin after exposure to ultra-violet irradiation,
normally sunlight, or received from the diet, the latter originates only from
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plant-derived foods (Haussler et al. 2012). In the body vitamin D goes through
25-hydroxylation in the liver and is converted in the kidney to 1,25-dihydroxy
vitamin D (1,25(OH)2D),  i.e.  calcitriol,  which  is  the  active  form of  vitamin  D
(Bergwitz and Jüppner 2010).  Circulating 25-hydroxy vitamin D (25(OH)D)
describes the vitamin D status in the body. Cytochrome P 2R1 (CYP2R1) is
responsible for 25-hydroxylation. Cytochrome P 27B1 (CYP27B1), the enzyme
responsible for 1–α-hydroxylation in the kidney, is induced by calcitonin, PTH,
hypocalcemia and hypophosphatemia. FGF23, hypercalcemia and
hyperphosphatemia repress CYP27B1 expression (Haussler et al. 2012), and
fibroblast growth factor 7 and secreted frizzled-related protein-4 seem to
downregulate this synthesis. FGF23 and 1,25(OH)2D also induce activity of
renal cytochrome P 24A1 (CYP24A1) expression which converts 25(OH)D and
1,25(OH)2D into inactive metabolites (Haussler et al. 2012).
Fibroblast growth factor 23 and Klotho
FGF23 is the major regulator of renal Pi handling (Ketteler et al. 2013). FGF23,
which needs Klotho as it’s co-receptor, is produced in osteocytes and
osteoblasts (Ketteler et al. 2013) and secreted from bone by an unknown
mechanism (Kuro-o 2013). Vitamin D receptor and 1,25(OH)2D induce
expression of FGF23 in bone, and increased S-Pi also accelerates the expression
of FGF23. Dentin matrix protein 1 and phosphate-regulating gene with
homologies to endopeptidases on the X chromosome suppress FGF23
production in bone, probably by indirect mechanisms (Bergwith and Jüppner
2010). FGF23 is an attenuator of 1,25(OH)2D action (Haussler et al. 2012).
1,25(OH)2D and dietary P induce synthesis of FGF23 (Bergwith and Jüppner
2010).  FGF23 facilitates kidney Pi handling by decreasing expression of
NaPi2a, NaPi2c and CYP27B1 in proximal tubules, thus, increasing urinary Pi
excretion. Many organs have FGF receptors, but Klotho is expressed only in the
distal tubulus, parathyroid gland chief cells and the choroid plexus of the brain.
Klotho is needed to improve the affinity of FGF receptors to FGF23.
FGF23 seems to follow an inherent circadian rhythm, and both intact FGF23
and carboxy-terminal  FGF23 (C-terminal FGF23) concentrations have been
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shown to increase in humans after feeding a high P diet (Vervloet et al. 2011).
Intact  FGF23 is  known to  response  more  sensitively  to  dietary  P  load  than  C-
terminal FGF23 (Burnett et al. 2006). It is also claimed that due to high dietary
P load, FGF23 increases only when high P intake is continuous (Block et al.
2013, Uribarri and Calvo 2013).
All of these P metabolism-regulating hormones (parathyroid hormone, FGF-23,
and 1,25(OH)2D) have been independently associated with adverse bone and
CVD health aspects even when S-Pi concentrations have been in the normal
range (Uribarri and Calvo 2013).
2.2. Sources and bioavailability of dietary phosphorus
P occurs widely in foodstuffs, but the highest contents are in protein-rich foods,
including meat, fish, eggs, dairy, legumes, whole-grain cereals, nuts and seeds
(Kalantar-Zadeh et al. 2010). Inorganic Pi’s and organic starch-based Pi’s are
used as food additives in various foodstuffs (Kalantar-Zadeh et al. 2010). Also
some dietary supplements and some drugs contain P (Uribarri 2013). Tap water
also  contains  P,  albeit  in  very  small  amounts  (EFSA  2005).  P  content  of
drinking water is legally restricted to 2.2 mg/l (European Union 1980). In
foodstuffs  P  occurs  in  the  form  of  Pi  but  nutritional  recommendations  and
nutrient contents of foodstuffs are reported as P. Table 3 displays P contents of
selected foodstuffs.
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2.2.1. Natural sources
Animal-based foods
In foodstuffs containing muscle protein (meat, poultry, fish), P is bound to
amino acid side chains, which are released during the digestion process as
inorganic P (Massey 2003). P in animals occurs as nucleoproteins,
phosphoproteins, phospholipids, and nucleotides and is also present in body
fluids and some tissues (Molins 1991). The most important phosphoproteins
found in foods are ovalbumin in eggs and casein in milk (Molins 1991). In milk,
P exists in organic and inorganic forms (Gauchelli 2011). One-third occurs as
inorganic P; 20% in esterbound casein amino acids, 40% in caseinate micelles,
and  the  rest  as  water-  and  fat-soluble  esters  (Uribarri  and  Calvo  2003).  The
organic form is bound to organic molecules such as casein, phospholipids,
DNA, RNA, nucleocides, nucleotides, and sugar Pi’s (Gauchelli 2011).
Inorganic  P  exists  as  Pi  ions,  and  the  distribution  between  different  Pi  forms
depends on pH (Gauchelli 2011). In processing of milk, part of Pi can be
transferred to aqueous phase. Some of the Pi is lost to whey in cheese
processing (Gaucheron 2011), which explains the differing Pi contents in
different dairy products.
Table 3. Phosphorus (P) contents of selected foodstuffs  (Institution for Health and Welfare 2011).
Foodstuff P (mg/100g) Foodstuff P (mg/100g)
Milk. 1.5% fat 90 Beef, raw 172
Edam cheese 510 Pork, raw 158
Processed cheese, fat 27-35% 360 Smoked ham 200
Processed cheese, fat 5% 1570 Turkey cold cut 260
Oat flakes 430 Pizza minced meat, pork-beef 149.7
Oat porridge 54.3 Tomato 30
Rye bread 229.1 Orange, peeled 23
(rye flour, wheat flour) Milk chocolate 300
Wheat flour 95 Cola drink 15
Eggwhite 11 Soft drink 2
Egg yellow 540 Apple juice 6
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Plant-based foods
Phytic acid i.e. myo-inositol hexakisphosphoric acid (C6H18O24P6) is a natural P
compound in many plant-based foods (Figure 3). Phytic acid and its salts are
commonly called phytates (Reddy and Sathe 2002). In grains and seeds most of
the  P  is  in  the  form  of  phytate,  which  stores  inositol  and  P  (Reddy  2002).
However, small amounts of P in plant products occur as phospholipids (Molins
1991).
Figure 3. Chemical structure of phytic acid.
Grains and seeds contain reasonably high amounts of phytate. Legumes are
defined as dicotyledonous seeds, thus, they also contain phytate. Nuts also have
high amounts of phytate compared with tubers, fruits, leafy products and
vegetables (Reddy et al. 2002). Among leafy products and vegetables, tomatoes
and okra contain high amounts of phytate, but no phytate is detected in many
fruits (Reddy et al. 2002). However, in cereals phytate constitutes the majority
of TP; in wheat 60-80%, in barley 55-70%, in oat 49%, in rye 38-66%, in
brown rice  74-81%,  and  in  polished  rice  51-61% of  TP occurs  in  the  form of
phytate (Reddy 2002). Because phytate is present in the outer layers of grains,
in whole-grain cereals phytate contents are greater than in raffinated products.
Phytate constitutes 50-70% of TP in soybeans, 27-87% in lentils, 40-95% in
chickpeas, 40-95% in broad beans, 57-82% in peanuts, 36-53% peas, and 95%
in tofu (Reddy 2002). In some tubers and fruits phytate P accounts for 20-34%
of TP (Reddy 2002).
28
Phytate can be degraded during processing of foodstuffs or in the intestine
(Sandberg 2002); however, the capability of the human intestine to degrade
phytate is limited (Iqbal et al. 1994). Phytase enzymes are responsible for the
enzymatic degradation: they appear in plants, microbes, and some animal
tissues (Sandberg and Andlid 2002). Non-enzymatic degradation of phytate
occurs at a low pH or at high temperatures and pressure. Phytate is degraded to
lower inositol phosphates (IP5, IP4, IP3, IP2, IP), and the same process forms
bioavailable, inorganic Pi (Sandberg 2002). Phytate is thermostable, and thus, it
does not degrade easily with cooking, autoclaving, roasting or with other
traditional heat processing methods (Sathe and Venkatachalam 2002).
Hydrolysis of phytate during fermentation and bread-making is affected by
many variables such as type and freshness of flours, use of yeast, pH of dough,
water content, possible fermentation, leavening time and temperature (Türk et
al. 1996, Sathe and Venkatachalam 2002). The effects of soaking on phytate
hydrolysis depend on the soaking time and temperature. Because phytate is
water-soluble, removal of soaking water has an impact on the final phytate
content of the product (Sathe and Venkatachalam 2002). Phytates may also
chelate with other minerals and impair bioavailability of Ca, iron and zinc in the
foodstuffs (Lopez et al. 2002).
2.2.2. Other sources
Food additive phosphates (FAPs) are used for a number of reasons; they enable
food products to achieve, for example, better texture, taste, emulsification,
acidification, leavening, anti-caking, moisture binding, antimicrobial action,
color stability, iron binding, buffering, and freeze-thaw stability (Uribarri and
Calvo 2013). In lean meat products (processed beef, pork, and chicken), FAPs
are used to maintain tenderness and moisture during cooking (Uribarri 2013). A
mixture of water, salt and sodium phosphate can be added to spice up meat
products and prevent their drying. FAPs are used in ham, bacon and cold cuts as
anti-oxidizing agents, stabilizing agents, and agents to improve taste and color.
Also frozen fish products can be rinsed with sodium phosphate solution prior to
freezing to prevent loss of protein during the thawing process. In dry food
mixes, e.g. soups, FAPs are used as anti-caking agents. Also some canned fish
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products contain FAPs. Without FAPs, the shelf-life of many foodstuffs would
be shorter (Uribarri 2007). Further, it should be noted that some Ca-enriched
products (e.g. soy drinks, other milk alternatives, and fortified juices) contain Pi
in the form of CaPi (Fitzpatrick and Heaney 2003, Kung 2010). Moreover,
some bakery products (cookies, biscuits, cakes, muffins) contain FAPs
originated from baking powder. Phosphoric acid is used as an acidity regulator
in cola beverages, and some countries also in other beverages. Table 4 displays
approved FAPs, their E codes, and examples of products containing specific
additives.
In  the  European  Union,  the  use  of  FAPs  is  regulated  by  a  Commission
Regulation (European Union 2011). Legally allowed maximum amounts of
FAPs are calculated as phosphorus pentoxide (P2O5). One mg of P corresponds
to 2.29 mg P2O5.  The  maximum  amount  allowed  varies  with  the  regulatory
classification  of  the  foodstuff;  starch  Pi’s  are  usually  distinguished  from  the
others,  and  their  addition  to  products  is  often  allowed quantum satis. For
breakfast sausages and processed meat, the maximum amount of FAP is 5000
mg/kg (P2O5). For processed cheeses the maximum amount is 20 000 mg/kg
(P2O5), while for unripened cheeses the amount is 2000 mg/kg (P2O5). For
breakfast cereals, spreadable fats, and frozen potatoes, the maximum is 5000
mg/kg (P2O5). For many foods, e.g. baby foods, FAP addition is not allowed
(European Union 2011).
A market survey done in Finland (Suurseppä et al. 2001) showed that
approximately 10% of food products on the market contain FAPs. After Finland
joined the European Union, the food additive contents of foodstuffs became
significantly higher due to more generous allowances in European Union
legislation. FAP-content in cold cuts and sausages was doubled and that in liver
pates rose by 25%, even though the levels were within allowed limits (20% of
the maximum, earlier 30%) (Blomberg and Penttilä 1999). The maximum FAP
amounts in sausages were tripled relative to the situation of the earlier
legislation. However, the FAP levels in the analyzed products were far below
the maximum limits, even though contents in processed cheeses were fairly
high (Suurseppä et  al.  2001).  When comparing the P content based of analysis
with that provided by manufacturers,  about half  of P in sausages seemed to be
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Table 4.Phosphorus-containing food additives and their E codes (EVIRA 2011).
Additive E code Examples of products
Antioxidizing agents
Orthophosphates
Phosphoric acid E338 cola beverages
Monosodium phosphate E339 puddings, cookies,
Disodium phosphate E339 sweet pies
Trisodium phosphate E339
Monopotassium phosphate E340 cheese, ice cream,
Dipotassium phosphate E340  breakfast cereals
Tripotassium phosphate E340
Monocalcium phosphate E341 enriched soya drinks,
Dicalcium phosphate E341 salad dressings
Tricalcium phosphate E341
Magnesium phosphates
Monomagnesium phosphate E343 cheese, ice cream,
Dimagnesium phosphate E343 dry food mixes
Emulsifiers, stabilizers, thickening agents
Diphosphates i.e. pyrophosphates
Disodium phosphate E450 meat products
Trisodium phosphate E450 (sausages, frankfurters),
Tetrasodium phosphate E450 processed cheeses, sausages,
Tetrapotassium phosphate E450 marinated meats,
Dicalcium phosphate E450 products containing
Calcium di hydrogen phosphate E450 baking powder
Triphosphates
Pentasodium phosphate E451 sausages, frankfurters,
Pentapotassium phosphate E451 meatballs
Polyphosphates
Sodium polyphosphate E452 processed cheeses, sausages,
Potassium polyphosphate E452 frankfurters, meatballs
Sodium calcium polyphosphate E452
Calcium polyphosphate E452
Starch phosphates
Mono-starch phosphate E1410 cold cuts, barbeque sauces,
Di-starch phosphate E1012 ready to eat pizzas,
Phosphated di-starch phosphate E1013 hamburgers
Acetylated di-starch phosphate E1414
Hydroxy propyl di-starch phosphate E1442
Anti-caking agents
Sodium aluminium phosphate (sour) E541 meat products, cup soups
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originating from FAPs (Suurseppä et al. 2001). However, in the United States
the  use  of  FAPs  is  more  common  than  in  Finland.  According  to  León  et  al.
(2013), 44% of the 2394 best-selling branded grocery products contained FAPs;
the most common were frozen foods (72%), dry food mixes (70%), packaged
meat (65%), bakery goods (57%), soups (54%) and yogurts (50%). In their
study, these products were matched to similar FAP-free products and P contents
were analyzed. FAP-containing products had significantly higher P content than
regular products. Authors also collected meals based on FAP-containing
foodstuffs and regular foodstuffs, and they noticed that the difference between
the mean P intakes was as high as the recommended daily allowance for P
intake (736 mg/d) when consuming FAP-containing products. Carrigan et al.
(2014) compared low-FAP and high-FAP meals based on 4-day menus
developed by a specific nutritional software, and found that the intake of P from
additives may reach harmful levels at least in kidney patients. Based on earlier
data in the United States, the estimations of FAP intake have been criticized as
being too low (Carrigan et al. 2014). The current use of FAP-containing
products in Finland is unknown. The only study investigating FAP contents of
foodstuffs in Finland was published in 2001 (Suurseppä et al. 2001). Since then,
the market shares of products have changed, new products have become
available, and food consumption patterns have changed (Mäkelä et al. 2008).
Also some dietary supplements may contain P (EFSA 2005). In a British study
of multivitamin supplements, the P contents in supplements ranged between 15
to 1100 mg/portion (EFSA 2005). The contribution of these supplements to TP
intake is, however, quite low at the population level. The NHANES 2007-2008
data in the United States showed that average P intake via supplements was 108
mg/day/portion (range 31-130 mg/d) (Uribarri 2013). To date, P contents of
dietary supplements in Finland have not been analyzed.
Recently, concern has arisen on P content of the inactive ingredients in both
prescription and over-the-counter medications (Uribarri 2013). According to
Uribarri, these medications can cause a rise in TP intake if many P-containing
medications are used at the same time, and Uribarri notes that in the
management of CKD this can cause problems when estimating the TP intake on
P-restricted diets. According to Calvo and Park (1996), also packaging material
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and other P-containing compounds used in the manufacturing process may end
up in foodstuffs, but they consider the effect on TP intake to be negligible.
2.2.4. Methods for assessment phosphorus contents and bioavailability in
foodstuffs
2.2.4.1. Basic chemical methods to analyze phosphorus contents
Different chemical methods can be used to analyze the P content in foodstuffs.
However, because foods have complex textures and P can be bound to other
elements,  the same methods as used for pure Pi solutions cannot be used. The
samples are usually pre-treated, e.g. the fat is removed, before the analysis.  In
colorimetric methods, the P content in foodstuffs is assessed based on the
intensity of the color formed in the reaction. The color can be assessed by either
a method based on formation of ammonium phosphomolybdate, which is
reduced to ammonium blue (Olson and Summers 1982, Nordic Committee on
Food Analysis 1994), or a molybdate vanadate method, where P reacts with
molybdate vanadate complex and forms a yellow color (Olson and Summers
1982, AOAC 965.17, Phosphorus in animal feed and pet food). This method is
not as precise as the former one, but it can be used for the assessment of higher
P contents. Most of the P contents in foodstuffs in the Finnish food composition
database Fineli®, especially cereals, are analyzed using this method (Varo 1980).
In titrimetric methods (AOAC Official method 964.06 Phosphorus in Animal
Feed, AOAC Official Method 948.09 Phosphorus in flour), the added
phenoliphtalein forms a pink color in the titrated solution. Molybdate solution
and Na hydroxide can be used as a reagent solution in the first phase, and either
Mg nitrate or molybdate solution in the second phase.
P contents can also be assessed by plasma-atomic emission spectrometry, but
not by atomic absorption spectrometry or atomic fluorescence spectrometry
(Lajunen 1986). In this method, the high temperature produces kinetic energy
for  the  particles,  which  transforms the  atoms to  an  excited  stage  and  ions  to  a
higher level, where their excess energy is emitted as photons. Each compound
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emits its own radiation with many wave-lengths. The emission forms a
spectrum, the compounds of which can be recognized and the contents analyzed.
Inductively coupled plasma mass spectrometer (ICP-MS) is one of these plasma
emission spectrometry methods. In ICP-MS, the recognition and sorting of ions
is based on their mass-charge ratio. The device is sensitive and the repeatability
of the measurements is good (PerkinElmerSciex Instruments 2001). Also
inductively coupled plasma optical emission spectrometry (ICP-OES) and
inductively coupled plasma atomic emission spectrometry (ICP-AES) can be
used to analyze P contents in foodstuffs; with these techniques, the intensity of
the emission describes the concentration of the element in the sample.
2.2.4.2. Methods to assess mineral bioavailability
In vivo methods
Methods for assessment of mineral bioavailability in vivo utilize living
organisms such as animals, humans and plants (Hur et al. 2011). These methods
may, for example, investigate mineral contents in serum or urine, mineral
balance in the presence of stable or radioactive compounds, or effects of the
mineral on target organs (Heaney 2001). When evaluating only serum
concentrations, the strictly regulated metabolism may not result in dose-
dependent changes in concentrations, and moreover, for many nutrients gold
standards are not available as biomarkers of bioavailability. When analyzing
only urine excretion, it is important to take into account the glomerulus
filtration rate (GFR), which depends on the subject and causes biological
changes in the results. Investigating the impact on target organs is effective, but
biological responses differ between subjects. Radioactive methods are sensitive,
quick, and easy. A labeled isotope, stable or radioactive, can be used to
determine the amount of absorbed mineral. Also ileostomic patients have been
used as subjects to investigate mineral bioavailability because their intestinal
contents can easily be accessed (Kivistö et al. 1986, Sandberg et al. 1987,
Sandberg et al. 1988). It is notable that in ileostomic patients only absorption in
the area of small intestine can be evaluated, not possible absorption in the colon
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(Kivistö et al. 1986). Generally, human studies are time-consuming, expensive
and difficult to carry out (Sandberg 2005).
Using animal studies to investigate mineral bioavailability also has some
drawback due to differences between animals and humans in mineral needs and
absorption.  For  example,  Fe  absorption  in  rats  is  dissimilar  to  that  in  humans,
thus hindering extrapolation of results to humans (Sandberg 2005). Rats have
phytase activity in their gut, while humans have only marginal phytase activity
(Hotz 2005), affecting the results when studying bioavailability of plant-based
foodstuffs.
In vitro methods
Cells or biological molecules can also be studied outside their normal biological
context. In vitro methods are faster, less expensive, and easier to control than in
vivo methods (Sandberg 2005). In vitro methods usually mimic the processing
of  food  in  the  alimentary  tract.  In in vitro methods evaluating mineral
bioavailability, the foodstuff is first digested enzymatically (e.g. by alpha-
amylase, pepsin and pancreatine) and the rest of the processing depends on the
filtration method chosen. In in vitro dialysis/solubility methods, the digestion is
two-phased: first the processing of food in the alimentary tract is mimicked and
then the sample is dialyzed through a half-permeable membrane based on
molecular weight describing the absorption process (Sandberg 2005).
Depending on the method, the incubation times, enzymes used, and end
processing  are  variable  (Hur  et  al.  2011).  Restrictions  of in vitro methods are
that the interaction between the alimentary tract and food or food components
cannot be measured (Sandberg 2005). In practice, the transit time in the
alimentary tract depends on the content of the meal, and absorption capability
of the different parts of the alimentary tract differs. The content and
concentrations of alimentary enzymes also depend on the content of the meal.
Neither intestinal microbiota nor circulation exist in in vitro methods.
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2.3. Gaps in the knowledge on intake and bioavailability of
dietary phosphorus
2.3.1. Food additive phosphorus intake
When assessing the P contents in foodstuffs, the natural P and FAP cannot be
distinguished analytically (Suurseppä et al. 2001), and thus, P contents in food
composition databases are reported as total P. Moreover, in food composition
databases, P contents of the recipe-based foodstuffs are calculated based on
nutrient contents of raw materials, and not on chemically analyzed values
(National  Institute  for  Health  and  Welfare  2011).  Thus,  the  amounts  of  FAPs
may have not been taken into account. The consumption of ready-to-eat meals
has increased four-fold over the last two decades in Finland (Mäkelä et al.
2008), and food composition databases have not taken into account possible
FAPs in these foodstuffs (Oenning et al. 1988, Sullivan et al. 2007).  Thus,
often the only way to obtain information about FAP contents is from the
manufacturers, which can be problematic (Calvo and Park 1996). Voluntary
labeling  of  P  contents  in  foodstuffs  has  not  been  popular  in  the  United  States,
even though the National Kidney Association recommends labeling (Uribarri
and Calvo 2013). However, in the European Union, the legislation requires that
any food additives used are listed as E codes or their names on the package
(European Union 2011).
In the United States, the estimated FAP intake in 1979 was 320 mg/day,
approximately 20-30 % of total P intake (Greger and Krystofiak 1982). The P
intake from additives in the United States has been estimated to have increased
from 470 mg/d in 1990 to 1000 mg/d in 2012 – now with 50% of P intake
coming from additives as “hidden phosphorus” (Winger et al. 2012).
Information about the use of FAPs in Finland is scarce and out of date. Finnish
Food Authority and Customs Laboratory conducted a survey of FAP-containing
foodstuffs  in  2000.  Based  on  their  results,  the  main  sources  of  FAPs  were
sausages and other meat products, baked goods leavened with baking powder,
and some ready-to-eat and processed meals such as pizza (Suurseppä et al.
2001). Also phosphoric acid-containing cola beverages were considered a
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potential high-FAP source. The authors concluded that FAP intake can be
excessive in small children or persons consuming particular products, e.g.
sausages and other processed meat products or cola beverages in abundance. An
earlier survey showed that mean FAP intake from meat products was 13 mg/d
among women and 38 mg/d among men (Ovaskainen et al. 2000). The mean
intake among adults was 25 mg/d. In this survey, only FAP intake from meat
products was estimated; food consumption data was based on in the National
FINDIET Study 1997, and analytical values were derived from Blomberg and
Penttilä’s  surveys  (1999).  However,  the  FAP  contents  in  the  products  were
clearly lower than the allowed maximum amounts in foodstuffs (Blomberg and
Penttilä 1999). Further, the current FAP intake in Finland is not known due to
lack of comprehensive studies.
Oenning et al. (1988) compared P and Ca intake based on chemically analyzed
results and nutrient databases. On the basis of database values, the P intake was
15-25% lower than when it was analyzed chemically, although the correlation
between the methods in Ca intake was good. This may cause underestimation of
the  true  P  intake.  Most  studies  comparing  P  contents  of  FAP-enhanced  and
regular products are conducted on animal products (Sherman and Mehta 2009a,
Sherman and Mehta 2009b, Benini et al. 2011). Sullivan et al. (2007) did a
survey about chicken products: 35 of the analyzed 38 chicken products
contained FAPs (92%). In almost all FAP-containing products, the P contents
were higher than content expected from nutrient databases. P contents between
manufacturers differed by up to 100 mg/100 g product. Researchers concluded
that additives seemingly increased P content of chicken products. Recently,
Carrigan et al. (2014) analyzed P contents of high- and low-FAP-containing
meals over an entire day, and surprisingly, no significant differences were
found between calculated and analyzed P content of high-FAP-containing meals,
contradicting earlier results. Nevertheless, in examining the low-FAP-
containing meals, the P content between calculated and analyzed content did
show a difference. Calvo and Tucker (2013) propose as an important future
work to improve food composition databases that the natural and additive
sources of P be identified.
37
2.3.2. Bioavailability of phosphorus
FAP-containing foodstuffs have been shown to cause more adverse effects in
Ca and bone metabolism than foods without FAPs (Bell et al. 1977, Kemi et al.
2006, Karp et al. 2007, Karp et al. 2012) indicating better bioavailability of
FAPs, however, in above-mentioned studies only in terms of mineral
metabolism markers. No differences have emerged between different forms of
FAPs, e.g. mono- and polyphosphates, concerning mineral metabolism (Karp et
al. 2013). Also the bioavailability of P in animal origin foodstuffs has been
stated to be better than in vegetable origin foodstuffs (Moe et al. 2011, Karp et
al. 2012). In the whole-foods approach intervention study of Karp et al. (2007),
the metabolic response was different for different foods (cheese, meat, whole-
grain), indicating different bioavailability. However, no generally reliable
methods to assess bioavailability of P in the foodstuffs have been developed.
Benini et al. (2011) and Cupisti et al. (2012) have developed methods to assess
different fractions of soluble P in meat products with or without FAPs, however,
these methods need further development to be used in P analysis of other
foodstuffs.
Further, the recent study of Chang et al. (2014a) instigated discussion about the
assessment of P bioavailability (McCarty 2014, Chang et al. 2014b). McCarty
paid attention to the lower bioavailability of plant-derived P and proposed use
of a correction factor in P intake for plant-derived P. However, according to
Chang  et  al.,  correction  factors  are  likely  to  introduce  error  into  results  until
reliable methods are developed to estimate P bioavailability. The authors further
stated  that  problems  are  caused  by  unknown  exposure  to  FAPs  as  well  as  by
food preparation. They recommended the use of 24-h urine Pi excretion
measurement, which has been shown to be a reliable method for estimating true
dietary P intake (Morimoto et al. 2014). However, 24-h urine collections have
not been available in many studies, including that of Chang et al. Calvo and
Tucker (2013) propose the use of algorithms to better quantify P bioavailability,
thus producing better estimates for actual P intake. Thus, in addition to these,
there  is  a  need  to  develop  a  method  to  analyze  bioavailable  P  contents  in
foodstuffs.
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2.4. Phosphorus, vascular calcification and cardiovascular
diseases
2.4.1. Calcification and cardiovascular diseases
Mineralization occurs in normal bone, but when it occurs in soft tissue and not
as a result of aging, it is called ectopic calcification. In the vascular system, this
is a pathological condition due to mineral (mostly Ca and Pi) deposition in the
vascular vessel wall (Marulanda et al. 2014). Vascular calcification is
associated with atherosclerosis, diabetes, kidney disease, and some genetic and
metabolic disorders (Wu et al. 2013). It predicts independently cardiovascular
events in the normal population, renal patients, and diabetics (Marulanda et al.
2014). Figure 4 presents the nomenclature of biological calcifications.
Figure 4. Nomenclature of biological calcifications (adapted from Lanzer et al.
2014).
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Vascular calcification comprises two distinct disorders: intimal (atherosclerotic)
and medial calcification (Mönckebergs sclerosis) (Lanzer et al. 2014).
Knowledge about molecular mechanisms in vascular calcification is growing.
Deposition of CaPi i.e. hydroxyapatite, different initiating and propagating
molecular mechanisms, and diverse crystalline compositions of Ca apatite
crystals can be present in vascular calcification, in both intimal and medial
calcification (Lanzer et al. 2014). Both of these calcifications result in ectopic
vascular calcification, but the triggering biochemical cascades between intimal
and medial calcification differ; in intimal calcification atheroplaque is formed,
but in medial calcification the cascades are initiated by damages to elastic fibers
(Lanzer et al. 2014). Figure 5 presents a cross-section of a normal vessel.
Normally, the intimal layer consists of endothelial cells and a small amount of
connective tissue. In the case of atherosclerosis, inflammation, thickening, and
calcification occur. Calcification seems to increase atheroma plaque rupture risk,
mainly in older persons with heavily calcified arteries (Sakakura et al. 2013).
Further, media consists of smooth muscle cells and an elastin-rich extracellular
matrix, and medial calcification occurs in the elastic lamina. Medial
calcification, affecting diabetics, renal patients, persons with osteoporosis, and
hypertension patients, leads to stiffening of the arterial wall, is associated with
elevated blood pressure, and entails a higher risk of cardiovascular mortality
(Wu et al. 2013).
Figure 5. Cross-section of a vessel.
40
Vascular calcification was earlier considered a passive phenomenon occurring
within  aging,  but  now  it  is  known  to  be  an  active  process  with  inductive  and
inhibitive reactions (Wu et al. 2013). The process of calcification is similar to
bone formation; the same mediators participate in both processes, and in
calcification vascular cells undergo a phenotypic change to osteoblast-like cells.
The major mechanisms revealed thus far for calcification are disturbed
anticalcific processes, induction of osteochondrogenesis, cell death,
abnormalities in Ca and Pi homeostasis, formation and circulation of
calciprotein particles, and modifications in the matrix (Wu et al. 2013).
Calcified vascular smooth muscle cells express the same proteins as osteoblasts
(Jono et al. 2000), and it has been suggested that the regulators of bone
metabolism, osteoprotegerin/RANK/RANK ligand axis, bone morphogen
protein, matrix Gla protein and fetuin A, may play a role in vascular
calcification, indicating mineralization similar to bone (van Campenhout and
Golledge 2009, Figueiredo et al. 2013). Further, CVD and osteoporosis have
been found to be associated in epidemiological studies (see den Uyl et al. 2011),
giving rise to the hypothesis that these two diseases may share some common
mechanisms  as  well  as  P’s  common  role  in  them.  Data  from  some
epidemiological studies indicates associations between vascular calcification,
impaired bone metabolism, and increased mortality (Cannata-Andia et al. 2011).
In renal patients these associations are even stronger.
Pi can participate in vascular calcification via multiple mechanisms (see Figure
6); for instance, cytotoxicity of Pi in cultivated vascular cells, Pi acting as an
endothelial toxin, and calciprotein particle production have been suggested to
underlie P’s role in CVD. Pi may act as an endothelial toxin because in the
presence of high Pi concentrations endothelial cells have been shown to impair
nitric oxide synthesis, increase reactive oxygen species generation, and undergo
apoptosis. Calciprotein particles induce phenotypical changes in vascular cells,
but it is notable that Pi is not the only factor that participates in crystal
formation and dissolution under conditions of high intracellular Ca level (Ellam
and Chico 2012).
Elevated S-Pi concentrations also provoke metabolic responses; increases in
FGF23 and PTH concentration, and decreases in calcitriol concentration, which
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may  also  underlie  P’s  role  in  vascular  health.  FGF23  can  directly  act  on
cardiomyocytes to promote left ventricular hypertrophy, which is also linked to
low vitamin  D status  and  elevated  S-PTH concentrations.  Calcitriol  can  act  in
the renin-angiotensin system by suppressing renal renin secretion; increased
renin concentration in blood has been shown to be a CVD risk factor. Calcitriol
can also interfere in CVD via anti-inflammatory effects on vascular
macrophages (McCarty and DiNicolantonio 2014).
Figure 6. Potential mechanisms by which phosphate could be involved in
vascular calcification (from Ellam and Chico 2012). Pi phosphate; FGF23 fibroblast
growth factor 23; ROS reactive oxygen species; VSMC vascular smooth muscle cells; PTH
parathyroid hormone; LVH left ventricular hypertrophy
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2.4.2. Methods to measure calcification and risk or progression of
atherosclerosis
Biomarkers of cardiovascular disease risk
Several biomarkers can be used to measure CVD risk. Traditional risk factors,
such as high concentrations of low-density lipoprotein cholesterol (LDL-C) and
high blood pressure are well known, but other factors have also been considered.
Inflammation markers measured in blood, such as white blood cells, C-reactive
protein (CRP), interleukin-6, and macrophage colony-stimulating factor are
connected to atherogenesis and plaque instability (Ikonomidis et al. 2008).
Recently, markers of mineral metabolism, such as osteocalcin, osteopontin,
bone morphogen protein, fetuin A, matrix Gla protein, and FGF23, have been
proposed to act as potential signaling molecules in arterial calcification (Everett
2010). The strongest evidence exists for associations between CVD and low
fetuin A, low undercarboxylated matrix Gla protein, and high FGF23
concentrations (Everett 2010). Nevertheless, more research about these markers
and prediction of CVD risk is required.
Intima-media thickness measurement and other non-invasive methods to
measure vascular calcification
Various non-invasive measurement methods can be used to assess vascular
calcification: arterial stiffness (a predictor of mortality and coronary heart
disease) with pulse wave analysis or pulse wave velocity, endothelial function
assessment with flow-mediated dilation, nitro-glycerin-mediated dilation and
brachial artery diameter measurement, peripheral flow with ankle-brachial
index either at rest or after exercise, and arterial wall thickness measurement in
terms of carotid intima-media thickness (cIMT) (Holewijn et al. 2010).
Coronary artery calcification can be measured by computed tomographic
angiocardiography  (Kwan  et  al.  2013).  However,  cIMT  measurement  is  the
most common and easiest method to use. cIMT measurement can be applied to
assess CVD risk and to monitor disease progression (O’Leary and Bots 2010).
Ultrasound imaging of the carotid gives reliable prediction of state of
43
atherosclerosis in other arteries, and the results correlate with histology of the
vessel. Many epidemiological studies have established cIMT as a marker of
subclinical atherosclerosis, and it is associated with CVD risk factors and with
prevalent and incident CVD (O’Leary and Bots 2010). Echoimaging of the
carotid has revealed that IMT correlates even in young persons with future
CVD risk (Raitakari et al. 2003).
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2.5. Current knowledge on phosphorus and cardiovascular
health from an epidemiological point of view
It has long been known that renal patients have impaired mineral metabolism
and are unable to excrete P properly, causing e.g. vascular calcification if not
treated with P-restricted diets (Qunibi et al. 2002). Information from short-term
and intervention studies in the general population suggests that high P intake
especially together with low Ca intake might be harmful for bone and Ca
metabolism (Calvo and Park 1996, Kärkkäinen and Lamberg-Allardt 1996,
Kemi et al. 2006, 2009, 2010). Also different P sources have different effects
on mineral metabolism: FAP seems to be more harmful than natural P (Karp et
al. 2007, Kemi et al. 2009).
In recent studies, some concern has been raised about excess dietary P intake
and vascular calcification, cancer, obesity, and hypertension (Anderson 2013).
Several organs and tissues are affected by elevated S-Pi concentrations
following  high  P  intake  (Anderson  2013).  High  S-Pi  concentrations  have  also
been speculated to cause inflammation, adipocyte hyperplasia, increased
triglyceride concentrations, insulin resistance, tumors, and Alzheimer’s disease,
although data for neurological conditions are limited (Anderson 2013).
Excessive  phosphorylation  of  protein  kinase  Akt  in  all  kinds  of  cells  has  been
suggested to be the main actor in cell metabolism associated with many chronic
diseases (e.g. cancer, type 2 diabetes, and neurological and cardiovascular
diseases) (Hers et al. 2011).
2.5.1. Serum phosphate and cardiovascular health
Decreased P excretion followed by hyperphosphatemia is associated with
progression of secondary hyperparathyroidism, renal osteodystrophy and
increased mortality and morbidity in dialysis patients (Slatopolsky and Delmez
1994, Block et al. 1998, Block et al. 2004). Hyperphosphatemia is also linked to
vascular calcification and CVD mortality in these patients (Block et al. 1998,
Qunibi et al. 2002, Kestenbaum et al. 2005). However, in the last decade, high
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S-Pi has been found to be associated with CVD risk also in large population-
based  studies  of  subjects  with  normal  renal  function  (Tonelli  et  al.  2005,
Dhingra et al. 2007, Foley et al. 2008). Table 5 presents the main findings of
studies on S-Pi and cardiovascular health in the general population. Elevated S-
Pi even in young persons was associated with atherosclerosis risk (Foley et al.
2009) and higher cIMT, a subclinical marker of atherosclerosis (Ruan et al.
2010).  In  an  earlier  study  of  Onufrak  et  al.  (2008),  S-Pi  was  associated  with
cIMT in males but not in females.  A Korean study (Park et  al.  2010) reported
an association between lower S-Pi and less coronary artery calcification. In the
MESA study in individuals with normal kidney function to moderate kidney
disease, high S-Pi was associated with high ankle brachial pressure, a marker of
arterial stiffness, however, not with arterial elasticity (Ix et al. 2009). Further,
Kendrick  et  al.  (2010)  showed  in  the  NHANES  population  that  S-Pi,  even
within normal reference limits, was associated with higher ankle brachial
pressure. In a longitudinal study, S-Pi independently predicted coronary artery
calcification (Tuttle and Short 2009). Larsson et al. (2010) reported that
elevated S-Pi was associated with risks of total, cardiovascular, and non-
cardiovascular mortality in the general population. High S-Pi was related to
greater risk of mortality also in the study of Sim et al. (2013).
The reported data on the deleterious effects of high S-Pi is from follow-up and
cross-sectional studies, but the only case-control study (Taylor et al. 2011)
failed  to  show  evidence  of  an  association  between  plasma  Pi  (P-Pi)  and
development of coronary heart disease. However, the subjects in the latter study
comprised only males. The only meta-analysis on the topic, including 24
studies, concluded that S-Pi non-linearly predict risk of CVD deaths/events and
total mortality, but not coronary heart disease events (Li et al. 2014).
Nevertheless, these data cannot be extrapolated to the general population
because also studies carried out on subjects with impaired kidney function
(CKD stages 1-2 [range 1-5]) and CVD were included.
Thus, results of these epidemiological studies support the evidence that high or
elevated-normal S-Pi concentrations may be harmful for vascular system and
health. Nevertheless, some studies show differences between the sexes in the
association between S-Pi concentrations and CVD risk factors. Some authors
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have stated that S-Pi could be considered a novel cholesterol, and in the future
Pi binders (now used in CKD patients) could possibly be used also in the
normal population in the prevention of CVD (Ketteler et al. 2013, McCarty and
DiNicolantonio 2014).
2.5.2. Dietary phosphorus and cardiovascular health
Several studies on the effects of high dietary P intake have been conducted with
uremic animal models that better describe circumstances under deficient kidney
functions (e.g. El-Abbadi et al. 2009, Nikolov et al. 2012, Che et al. 2013).
However, a high-P diet has increased vascular calcification in mice (Román-
García et al. 2010), and in ApoE-deficient mice reduced atherosclerosis
formation in an atherosclerotic condition, which was an unexpected result
(Shiota et al. 2011). Dietary P restriction also reduced vulnerability to high-
cholesterol diet-induced dyslipidemia in mice (Tanaka et al. 2013).
Only limited data are available on the effects of a high-P diet on cardiovascular
health  outside  CKD  in  humans  (see  Table  6).  Acute  high  P  intake  (1200  mg)
reduced endothelium-dependent flow-mediated brachial artery dilation in
eleven healthy men (Shuto et al. 2009). In the study of Yamamoto et al. (2013)
a high dietary P intake (assessed by food frequency questionnaires [FFQs]) in
subjects (n=4494, mean age 62 years) was associated with left ventricular
hypertrophy among women (highest P intake quintile 1346-4069 mg/d) but not
among men. Their data was adjusted for demographics, Na and energy intake,
lifestyle factors, comorbidities, and established left ventricular hypertrophy risk
factors. Chang et al. (2014a) showed in the NHANES cohort (n=2686, age 20-
80 years) that dietary P intake >1400 mg/d and P density of the diet >0.35
mg/kcal were associated with all-cause mortality. High P density (>0.35
mg/kcal) was associated with CVD mortality, but no such results were found
for total dietary P intake. Interestingly, also low P density (<0.35 mg/kcal) was
associated with increased mortality risk. In that study, P intake was assessed by
24-hour recalls, and the data was adjusted for demographics, CVD risk factors,
kidney function, and energy intake, and the results remained so when Na and
saturated fat intake were introduced as covariates. Neither differences between
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diet quality subgroups based on the Healthy Eating Index were perceived. In a
recent Korean study on subjects with preserved renal function, no association
between dietary P intake and coronary artery calcification was found (Kwak et
al.  2014),  but  the  mean  P  intakes  in  the  study  population  were  very  low,  less
than 800 mg/d.  However, because P and Ca interact (Peacock 2010), it is
important to consider intake of Ca as a confounding factor. These studies failed
to do this and also the sources of dietary P intake were not separated, which
may explain the finding that no association between dietary intake of P and
coronary artery calcification.
Some cross-sectional population-based studies propose that high dietary P
intake is associated with lower blood pressure (Joffres et al. 1987, Beydoun et
al. 2008, Elliott et al. 2010). However, the effects of confounding factors cannot
be excluded in these studies. In the study by Elliott et al., the study population
was  from  four  different  countries  with  differing  main  P  sources  and  total  P
intakes were not reported. Other limits of their study are high intercorrelations
between P and Ca intake and between P and Mg intake. Also Joffres et al.
(1987) reported high intercorrelations between the nutrients, and in the
multivariate analyses the data were adjusted only for age and body mass index
(BMI).  In the study of Beydoun et  al.  (2008),  in addition to P,  cheese and low
fat milk consumption were inversely associated with blood pressure, which may
reflect  more  the  role  of  dairy  products  than  P  itself.  Similarly,  Alonso  et  al.
(2010) showed in their prospective follow-up study on the MESA and ARIC
study populations (n=13 444, P intake measured by FFQ) that P from dairy
products,  but not from other sources was associated with lower baseline blood
pressure. The mean P intakes in the lowest quintiles were about 900-1000 mg/d,
compared with 1500 mg/d in the highest intake quintiles, within the overall
reported P intake range from 0 mg/d to 3570 mg/d. However, the intakes of
0mg/d can be questioned; that low intakes do not appear real, and those subjects
could have been excluded from the analyses. However, according to the authors,
dairy  products  (with  or  without  the  effects  of  P)  may  mainly  explain  the
negative association between P and blood pressure. When other dietary factors
(e.g. intakes of Ca, Mg, potassium) were introduced to the models, the effects
of dietary P on blood pressure were attenuated, but remained statistically
significant when all subjects were pooled in the analyses. Further, based on
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Table 6. Evidence on high dietary phosphorus (P) intake an d cardiovascular disease-related problems in animals and humans.
Refence Animal/human Amount of P outcome/association with high P intake
Román-García et al. 2010 animal high P diet increased vascular calcification
Shiota et al. 2011 animal high P diet reduced atherosclerosis in ApoE-deficient mice
Tanaka et al. 2013 animal P restriction reduced diet-induced dyslipidemia in mice
Shuto et al. 2009 human acute high P intake reduced endothelial function of vessels
Yamamoto et al. 2013 human high P intake increased left ventricular hypertrophy, only women
Alonso et al. 2010 human P from dairy, not other sources lower baseline blood pressure and reduced risk of hypertension
Elliott et al. 2008 human high P intake inverse association with hypertension
Chang et al. 2013 human high P intake increased all-cause mortality
50
other  studies,  it  is  more  likely  that  high  P  intake  impair  vascular  function  via
acute high S-Pi and thereby increases blood pressure (Shuto et al. 2009, Lanzer
et al. 2014).
Even though associations between both high S-Pi and dietary P intake and CVD
health have been reported, no associations between both S-Pi and dietary P
intake and CVD have been found in the same studies. Uribarri and Calvo (2014)
state in their editorial in the American Journal of Clinical Nutrition that the lack
of an association between dietary P and S-Pi (and CVD) is due to failure to take
into account several confounding factors. They propose that S-Pi is not a proper
indicator of dietary P intake, and the association between high S-Pi and CVD
might be due to some other reason.  This topic is now under active discussion,
and according to a recent opinion in the European Heart Journal, not only high
S-Pi  but  also  high  dietary  P  intake  has  been  proposed  a  potential  CVD  risk
factor (Ketteler et al. 2013).
2.5.3. Regulators of phosphate metabolism and cardiovascular health
Ellam and Chico (2012) proposed that Pi regulatory hormones may respond
better  to  dietary  P  load  than  only  S-Pi.  It  has  been  suggested  that  FGF23  or
PTH or other regulators of P metabolism could be the main reasons for the
detrimental  effects  of  P  (Uribarri  and  Calvo  2014).  PTH  and  FGF23  are  both
known to increase with high dietary P intake, FGF23 in a prolonged way, and
PTH also acutely, and persistently with continuous exposure to high P intake
(Block et al. 2013). PTH and FGF23 suppress the active metabolite of vitamin
D, 1,25(OH)2D, and all of these mediators have been associated independently
with adverse health effects even within normal S-Pi concentrations in healthy
subjects  (Block  et  al.  2013).  In  renal  patients,  many  studies  have  shown  that
elevated FGF23 was associated with CVD or mortality (e.g. Kendrick et al.
2011, Isakova et al. 2011). In patients with prevalent CVD, higher FGF23 was
independently associated with mortality (Parker et al. 2010), and Ix et al. (2012)
found that high FGF23 was associated with increased all-cause mortality and
heart failure incidence also in community-dwelling individuals without CKD,
although the association was stronger in CKD patients (Ix et  al.  2012).  FGF23
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has also been associated with left ventricular hypertrophy in longitudinal study
in older adults (Mirza et al. 2009). However, in the prospective case-control
study of Taylor et al. (2011) plasma FGF23 was not associated with incident
coronary heart disease among males.
Moreover, a meta-analysis of 15 prospective studies showed that high PTH was
associated with increased risk of CVD events (van Ballegooijen et al. 2013).
However, for total CVD events (10 studies included in the analysis) only three
of  the  studies  showed a  positive  association  between PTH and CVD,  with  the
rest  seven  studies  showing  no  association  (van  Ballegooijen  et  al.  2013).
Nevertheless, in a longitudinal study in older adults not included in the meta-
analysis,  high  PTH  even  within  normal  range,  was  associated  with  CVD
(Buizert  et  al.  2013).  In  the  same  study,  high  PTH  was  associated  with
abdominal aortic calcification among males, but not among females (Buizert et
al. 2013).
Even though low 25(OH)D status has been related to CVD, recent reviews state
that  the  causal  link  between  low  25(OH)D  status  and  CVD  remains  to  be
elucidated (Lamberg-Allardt et al. 2013, Cashman 2014).  From a mechanistic
point of view, however, low concentrations of 1,25(OH)2D, the active form of
vitamin D,  has been shown to have a potential role in CVD (Cashman 2014).
Thus far, no consensus exists about the role of regulators of P metabolism and
their role in CVD.
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3. Aims of the thesis
This thesis aims to offer new insights into the potential health risks related to
high dietary P intake in Finland by providing knowledge on the bioavailability
of dietary P, and on the association of high dietary P intake with cardiovascular
disease (CVD) risk factors in the general population. The first aim was to
investigate in vitro digestible  and  total  phosphorus  (DP  and  TP,  respectively)
contents in differently processed cereals and other selected plant-based
foodstuffs  using  a  new  analysis  method.  Another  aim  was  to  determine  at  a
public health level whether high dietary P intake, especially in the form of
highly absorbable food additive phosphorus (FAP), is associated with vascular
calcification in terms of high carotid intima-media thickness (cIMT), and thus,
with increased risk of CVD, in a middle-aged Finnish population. Previous to
this work no studies on these topics have been published. Specific research
questions were as follows:
I: Are there differences in in vitro DP and TP contents in differently
processed cereals? Does the processing affect the DP concentrations? Is the
analysis method of in vitro DP trustworthy?
II: Are there differences in in vitro DP and TP contents of selected
commonly used plant-based foods and beverages? Do the FAP-containing
foodstuffs have higher proportions of DP than FAP-free products?
III:  Is  high  dietary  P  intake  associated  with  higher  cIMT  in  a  general
middle-aged Finnish population in a cross-sectional design? Are there
differences in associations between total dietary P and FAP intake in cIMT?
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4. Subjects and methods
4.1. Food studies (Studies I and II)
4.1.1. Samples
Study I
The samples were different cereal products commonly used in Finland (Table 7).
The samples were bought at two local grocery stores in Helsinki in June 2007.
The rye sourdough originated from a bakery in Helsinki. All flours, grits, yeasts,
and breads were from the same batch to ensure homogeneity of the samples.
Three different kinds of breads were baked: sourdough rye bread, sourdough
wheat bread, and yeast-fermented (non-soured) wheat bread. Barley porridge
was made with barley grits, water, and salt. More information about the home-
baked samples is provided in Appendix (Table 1). All breads, doughs and
porridges were stored at -18ºC, and the dry products were stored at room
temperature until they were analyzed. Before the analysis, all dry samples were
mixed and homogenized in a blender (Braun 4250 Multimixture Machine,
Braun Ab, Frankfurt/M, Germany). The breads were also homogenized and one
sample of each was taken for analysis, for a total of five samples of one product.
In the final P analysis by ICP–MS, the samples were analyzed in duplicate.
Study II
Legumes and cereals are important sources of plant-based protein and P, and
thus, products from these food groups were included in the analyses (Table 8).
Further, foodstuffs containing FAPs, i.e. baking powder-leavened bakery
products as well phosphoric acid-containing cola beverages, were analyzed.
Among cereals and cola beverages, several labels were analyzed to clarify P
contents in the products of different manufacturers.
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To improve representativeness of the analyses in Study II, the focus was on the
nationally most popular products in each food category. Market shares of the
Sample n Sampling method Frozen (-18˚C) before analysis
Home-made/original products
Rye flour 5 Mixed -
Rye dough 5 1/dough +
Rye bread 5 1/bread, ground +
Wheat flour 5 Mixed -
Wheat dough 5 1/dough +
Wheat bread 5 1/bread, ground +
Soured wheat dough 5 1/dough +
Soured wheat bread 5 1/bread, ground +
Barley grit 5 Mixed, ground -
Barley porridge 5 1/porridge, ground +
Bakery products
Wheat bread 5 1/bread, ground +
Rye bread with potato 5 1/pack a +
Rye bread 5 1/bread, ground +
Table 7. Samples, n's, sampling method, and possible freezing before analysis in Study I.
(+ frozen before analysis, - not frozen before analysis,  a  from every pack one bread was ground to one sample)
Table 8.  Products analyzed in Study II.
Breads Sweet bakery products Seeds and beans Drinks
Rye bread pool Muffin pool a Sesame seed (with hull) Pepsi Max b
Rye crisp Sweet bun pool Tofu (firm) Coca-Cola light b
Small rye bread containing potato 1 Cookie pool Green bean Coca-Cola b
Small rye bread containing potato 2 Green pea (frozen) Cola pool b
Mixed grain bread with seeds Chickpea (soaked) Freeway Cola light b
Red lentil Beer
Green lentil
a Contains sodium polyphosphate as an additive
b  Contains phosphoric acid as an additive
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products  were  based  on  a  substudy  of  the  national  dietary  survey  FINDIET
2007 (Reinivuo et al. 2010). A subsample (50%) of the participants (n =1025)
of the FINDIET 2007 Study filled in a 5-day product purchase diary to
investigate the purchase and use of voluntarily fortified foods. A total of 930
subjects (91%) returned the diary, 918 (90%) of which were of acceptable
quality.  Each  food  item  was  assigned  with  a  food  identifier  from  the  Finnish
food composition database Fineli®, enabling data classification. Market shares
of each product were calculated by dividing the total amount (kg) of purchased
product by the total amount of purchased food in the same food class.
Of the most popular trademarks, 2-7 of each were pooled for each sample item.
The leading trademark in each sample category was analyzed as such. The
chosen sample items were purchased from grocery stores in the Helsinki area.
The number of purchased trademarks was twice the proportion of that item in
the pool (40% in the pool, corresponding to 8 subsamples). The minimum was
two subsamples for each pooled per trademark. The samples were homogenized
in a blender, packed into polyethylene bags, and stored at -20ºC until analysis.
The samples were analyzed with five replicates.
4.1.2. Study designs and hypotheses
Study I:  A new method for analysis of in vitro DP, indicating bioavailable P,
was developed, and the in vitro DP and TP contents of certain differently
processed cereals were determined. The hypothesis was that processed cereals
contain more DP than the unprocessed ones due to the baking processes for rye
and wheat breads and the effects of long processing time on barley porridges,
all of which may degrade phytate resulting in higher DP contents.
Study II: By the analysis method developed in Study I, the DP and TP contents
of different plant-based products considered to be good dietary P sources were
analyzed. The foodstuffs were chosen based on market shares, and the analyses
included both natural and FAP-enhanced products. The hypotheses were that
differences exist in DP and TP contents in the plant-based foodstuffs and the
proportion  of  DP  to  TP  is  lower  in  plant-based  FAP-free  products  than  in
products prepared with FAPs.
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4.1.3. Methods
4.1.3.1. Analysis of in vitro digestible phosphorus
The method for in vitro DP analysis is based on the method of Asp et al. (1983)
for enzymatic assay of insoluble and soluble dietary fiber. There, the proteins
and starch are degraded with alimentary enzymes and the mineral content in the
remaining fiber is analyzed. Ekholm et al. (2000, 2003) developed the method
for  the  analysis  of  soluble  minerals.  Figure  8  presents  the  flow-chart  of  the in
vitro DP analysis. Here, a sample (5 g) was placed in a 100-ml flask and mixed
with  50  ml  of  purified  water  (MilliQ,  Millipore  Corporation,  Bedford,  MA,
USA),  then  cooked  for  15  min  at  100ºC.  Then  0.4  ml  of  heat-stabile  alpha-
amylase Termamyl1 120 L (Novozym A/S, Bagsvaerd, Denmark) was added to
initiate starch degradation. Cooking for 15 min and adding of Termamyl1 (0.4
ml) was repeated two times. After the last addition, the mixture was cooked for
a further 15 min. The presence of any unhydrolyzed starch was verified with
I2/KI solution. If starch had been present, the color of the sample would have
changed to violet. Instead, it turned yellow, indicating the presence of no starch.
The  amount  of  the  enzyme  was  optimized  to  be  as  low  as  possible  to  avoid
excess mineral contamination. The pH of the sample was adjusted to 1.5 by 1 M
HCl. The pepsin (0.7 FIP-U/mg, E.C. 3.4.23.1, Merck, Darmstadt, Germany)
dissolved  in  purified  water  (0.5  g  in  10  ml)  was  added  to  the  sample  and  the
mixture was incubated at 40ºC for 60 min on a continuous shaker. Before the
pancreatin (8-U.S.P., Sigma–Aldrich, St Louis, MO, USA) was added, the pH
was adjusted to 6.8 by 1 M NaOH. The pancreatin mixed in purified water (0.5
g in 10 ml) was added to the sample,  which was incubated at  40ºC for 60 min
on a continuous shaker. After incubation, purified water was added to the
sample  until  it  weighed  100  g.  Half  of  the  sample  (50  g)  was  transferred  to  a
60-cm-long  dialysis  tube  (cut-off  point  2.4  nm,  size  5,  Medicell  International
Ltd.,  London,  UK).  The  samples  were  dialyzed  in  equilibrium dialysis  against
300 ml purified water overnight with 10 drops of chloroform (Merck) to avoid
bacterial growth. After dialysis the dialyzates were frozen (-18ºC). The rest of
the analysis differed between Studies I and II.
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Sample 5ga
↓
Pasting of starch
Adding of 100 ml H2O, 100˚C, 15 min
↓
    ↓
Testing the presence of starch
KI
↓
Hydrolyzing of protein
pH 1,5
Adding of  0.5 g pepsin
40˚C, 60 min
↓
Hydrolyzing of protein
pH 6.8
Adding of 0.5 g pancreatin
40˚C, 60 min
↓
Dialyzing
overnight against 300 ml H2O in 25˚C
↓
Freezing of dialyzateb
-18˚C  1.5-2 months
↓
Acid adding
10 ml of dialyzate
15 ml conc HNO3
↓
Wet digestion
↓
P analysis
by ICP-MS / ICP-OES
Figure 8. Flow-chart of enzyme preparations and digestible phosphorus analysis in
Studies I and II. asome of the samples were ground before freezing bfreezing was used to make the process easier,
HNO3=nitric acid, ICP-MS=inductively coupled plasma-mass spectrometry, ICP-OES=inductively coupled plasma-
optical emission spectrometry, KI=potassium chloride.
Hydrolyzing of  starch
Adding of  0.4 ml Termamyl®
100˚C, 15 min
repeated 3 times
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Study I
Two replicates of every dialyzate (10 ml) remained at room temperature with
15 ml of concentrated nitric acid (HNO3) (69.0–70.0%, J.T. Baker, Phillipsburg,
NJ,  USA)  in  a  wet  digestion  tube  and  later  processed  in  a  wet  digestion
apparatus (Foss 2040 Digestor, Foss Tecator, Hillerod, Denmark). The wet
digestion program for DP analysis is shown in Appendix (Table 2). Later, every
sample was moved quantitatively to a 25-ml flask by flushing the wet digestion
remnant with purified water and filling the flask to the 25-ml mark.
For the ICP–MS analysis, 400 ml of the sample were moved to an ICP tube.
Rhodium (1 ml, c = 1000 mg/l, AccuTraceTM Reference Standard Rhodium
1000 mg/l; AccuStandard, New Haven, CT, USA) was added as an internal
standard,  and the samples were diluted to 2% HNO3 (8.6 ml).  Five P standard
solutions (AccuTraceTM Reference Standard Phosphorus 1000 mg/ml;
AccuStandard) with concentrations of 100, 200, 400, 1000 and 2000 mg/l were
used. The standard curves were obtained at the above-mentioned concentrations.
The samples were analyzed by using an ICP–MS device (Elan6000
PerkinElmerSciex,  PerkinElmer,  Waltham,  MA,  USA)  using  the  isotope  31P.
DP contents were calculated as mean per 100 g/product. Percentages of DP/TP
(TP analysis described in Section 4.1.3.2.) were also calculated.
Study II
Ten milliliters of the dialyzate was digested in a microwave oven with 10 ml of
concentrated HNO3. The sample was transferred to a 50-ml volumetric flask
with purified water. The concentrations of P in the dialyzate were determined
by ICP-OES (Thermo Scientific iCAP 6000 Series ICP Spectrometer, Waltham,
MA, USA). The quantitation was performed by using an external calibration
curve with five different concentrations. P was analyzed radially with
wavelengths of 177.4, 178.2, 178.7, and 213.6 nm. The fat was removed from
samples if the fat content was more than 6-8%. Petroleum ether (200 ml, bp:
60ºC to 71ºC) was added and the suspension was agitated with a magnetic
stirrer at room temperature for 15 min. The solvent was filtered and the sample
was air-dried at room temperature overnight, and analyzed by ICP-OES.
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The results were calculated as means. DP contents of analyzed foods were
calculated per 100 g of the product. The percentages of DP/TP (TP analysis
described in Section 4.1.3.2.) were determined.
4.1.3.2. Analysis of total phosphorus
Study I
In the TP analysis a homogenized sample (0.5 g) was weighed in a tube, and the
sample remained in concentrated HNO3 (10 ml) overnight before wet digestion.
The wet digestion program is shown in Appendix (Table 2). After digestion the
samples were treated as in DP analysis and the TP content was analyzed by an
ICP-MS device using the isotope 31P.
Study II
The  food  sample  (0.5  g)  was  digested  in  a  microwave  oven  with  10  ml  of
concentrated HNO3. The sample was transferred to a 50-ml volumetric flask
with purified water, and the content of P was analyzed with ICP-OES.
TP contents of analyzed foods in Studies I and II were calculated per 100 g of
product.
4.1.3.3. Assay quality control
To avoid possible contamination, all glassware used in ICP analyses was acid-
washed (HNO3/HCl) and rinsed with purified water (MilliQ). The enzymes
used in DP analysis contain P, which could have affected the results. Therefore,
the amounts of P in all enzymes (i.e. the background level) were analyzed from
the same amount of enzymes as in the analysis without any substrate. These
values were taken into account in the results. To test accuracy and precision of
the analytical method, each determination set of the TP analysis included in
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duplicate (in Study II:  a single sample) two different reference samples,  NIST
1567a wheat flour standard reference material (National Institute of Standards
and Technology, Gaithersburg, MD, USA) and an in-house wheat flour
standard (Saari and Paaso 1980), both containing a known amount of P. To
estimate the repeatability of the method, in DP analysis an unofficial in-house
white wheat flour sample was used in duplicate as a reference material in each
determination set. All analyses were carried out at the Laboratory of General
Chemistry, at the Department of Appied Chemistry and Microbiology.
The measurement uncertainty was calculated taking into account all possible
sources of uncertainty in the analysis procedure and quantifying the uncertainty
according to the statistical methods (Ellison et al. 2000). Approximate
confidence interval of 95% was used, implying that 95% of the results are
inside the limits of measurement uncertainty. The calculations were performed
for both DP and TP.
4.1.3.1. Statistical analyses
The statistical analysis was performed by SPSS (Statistical Package for Social
Sciences for Windows, version 13.0.1, SPSS Inc., Chicago, IL, USA).
Statistical differences between the means of the TP and DP contents were tested
by paired t-test (Study I). In Study I, the home-baked breads were also tested by
paired t-test; the amount of DP in the bread and dough originating from 100 g
of  flour  was  compared  with  the  DP  amount  in  100  g  of  flour.  For  barley,  the
difference between the amount of grits from which 100 g of porridge originated
was  compared  with  the  amount  of  DP  in  100  g  of  porridge.  The  differences
were significant at p<0.05. The differences between the means of the groups in
the flours,  doughs,  and breads in Study I  were tested by F-test,  using one-way
analysis of variance (ANOVA) for repeated measures. The normality of the
data was first tested by Shapiro–Wilk’s test. The sphericity of the results of the
groups was tested, and if the sphericity assumption had been violated, a Huyhn-
Feldt adjustment was used.
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4.2. Human study (Study III)
4.2.1. Subjects
A randomly collected sample of 1920 subjects aged 37-47 years (50% males,
50% females) and living in the Helsinki area was derived from the Population
Register Center in Finland. Subjects were contacted by mail in November 2009
(1st sampling) and February 2010 (2nd sampling) and invited to participate in the
study.  A total  of 678 persons participated in the first  visit  to the research unit
either in January or March 2010, and 653 of these attended the second visit
during spring 2010 (discontuation for unknown reasons, n=25). Subjects were
middle-aged, and thus, possibly already had some changes in cIMT. The initial
exclusion criterion was pregnancy, and also post-menopausal females and
persons with impaired kidney functions (estimated GFR, i.e. eGFR, <60 ml/min)
were excluded from the analyses due to their improper P metabolism.
The study protocol of the study was approved by the Helsinki Uusimaa Hospital
District Ethics Committees. All subjects gave their informed consent to the
procedures, which were in accord with the Helsinki Declaration. They also were
informed that they could withdraw from the study and for any reason. After the
study, subjects received information about their dietary intake relative to the
nutritional recommendations as well as results on their vitamin D status (serum
25(OH)D concentrations) and tibial and radial bone mineral density compared
with the age-matched population. Medical experts checked the results, and if
health problems were perceived, the subjects were informed after the analyses
and advised to contact a local doctor.
4.2.2. Study design and hypothesis
The study design was cross-sectional and the study population comprised free-
living, middle-aged males and premenopausal females, i.e. the general
population. Associations among TP intake, P density of the diet, FAP intake,
and cIMT were investigated. Subjects visited the research unit two times during
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spring 2010. On the first visit, fasting blood samples were collected and
subjects were advised to fill in the study form, which included food records,
food frequency questionnaires (FFQ) concerning intakes of P, Ca, and vitamin
D intake, and a background questionnaire.  Before the second visit, subjects
were advised to abstain from caffeine-containing products and smoking for four
hours. During this visit the common cIMT was scanned by ultrasonography,
blood pressure was measured by an automatic device, and subjects’ height and
weight were measured. Some other measurements (e.g. bone mineral density
assessments) not included in the present study were also carried out; the power
calculation of the study is based on bone mineral density assessments (see
Section 4.2.3.4.). The hypothesis was that when taking into account the
potential confounding factors, high P intake, especially in the forms of FAP, is
associated with higher IMT, thus, high dietary P intake should be considered a
CVD risk factor in the general population.
4.2.3. Methods
4.2.3.1. Dietary intake and background data collection
Habitual dietary intake data of subjects were collected by 3-day food records,
which included two weekdays and one weekend day. The subjects were
instructed to maintain their normal food habits during the recording period and
to record all foods, beverages, and dietary supplements immediately after
consumption.  Nutrient intake was calculated using a computer-based program
(Diet 32 version 1.4.6.2, Aivo2000, Turku, Finland) based on the Finnish food
composition database Fineli® (Institution  of  Health  and  Welfare,  Helsinki,
Finland). Approximately 400 new recipes were added to the program to ensure
accurate calculation of nutrient intake. Vitamin D and Ca supplementation was
taken into account in the calculations. P intake was calculated as total P intake
(mg/d), and as P density of the diet [P intake (mg/d)/energy intake (kJ/d)].
FAP intake calculations were based on one-month food use frequency data,
which were collected by a validated FFQ concerning P intake, ranging from
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“less than one portion per month” to daily portions (Kemi 2010). The FFQ
included P sources in different food groups, distinguishing FAP-containing
foodstuffs from natural P-containing foodstuffs, and also including P sources
not consumed every day. For  FAP  intake  calculations,  products  known  to
contain FAP were chosen and separated these into food groups (meat products
like marinated meat, sausages, and cold cuts; cola beverages; processed cheeses,
Table 9). FAP intake from different sources was calculated from the portions of
FAP-containing foodstuffs as grams and recorded on the FFQ, using the
maximum amount of FAP allowed in the foodstuff according to European
Union regulations (meat products 5 g/kg; cola beverages 700 mg/L; processed
cheeses 20 g/kg (European Union 2011)). Only these products in which the
amount of added FAP is regulated were included in the analysis (for example,
starch-based FAPs were not included). Cookies were excluded from the
calculations because some do not contain FAPs. The subjects were divided into
tertiles of intake in each FAP group (meat products, cola beverages, processed
cheeses), with score 0 indicating the lowest intake tertile, score 1 the middle
tertile, and score 2 the highest tertile, and the scores from different FAP sources
were summed for each subject; thus, each person was given a score from zero to
six. Since no one received a score of 0, thus, the scoring was 1-6 and divided
the subjects into six groups of unequal size. However, the final group sizes
were sufficient for analysis of covariance (ANCOVA).
Background data were collected by a questionnaire covering disease history and
lifestyle factors such as smoking status (current/former or non-smoker),
physical activity, and state of menopause. Body mass index (BMI) was
calculated as weight (kg) / height (m)2. All self-reported forms were checked by
the researchers, and additional information was requested if needed.
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4.2.3.2. Measurement of the carotid intima-media thickness and blood
pressure
Common carotid artery IMT was measured by a semi-automatic measurement
program using high-resolution ultrasonography (Esaote MyLab30Gold, Firenze,
Italy).  The  image  is  based  on  high  ultrasound  frequencies,  which  reflect  from
the tissues in different ways.  In practice, this means that the thicker the white
line, i.e. the intima-media in the image, the more calcification occurs (Figure 7).
However, this technique does not distinguish between the intimal and medial
layers  of  the  artery  (O’Leary  and  Bots  2010).  Ultrasound  provides  a  two-
dimensional image, thus, either the far or near wall can be measured. The
consensus statement proposed that cIMT be used to measure the far wall of the
common carotid artery. Measurement of the near wall is not as reliable because
the ultrasound reflects from the adventitia to the intima, i.e. from the more
echoing part to the less echoing part, and the wall thickness can be suboptimal
(Stein et al. 2008). The thickness of the cIMT varies depending on cardiac cycle,
being thickest at the end of diastole and thinnest at the peak of the systole; thus,
Table 9. Food additive phosphate (FAP) -containing products included in FAP intake calculations.
FAP-containing product Portion size
Processed meat products
Processed, marinated chicken, turkey, beef, 1 steak (130 g)
pork, or other meat
Liver pâté and liver sausage, regular and light 1 tablespoon (15 g)
Sausages / frankfurters, regular and light 10 cm slice of big sausage, 3 frankfurters
 or 1 barbeque sausage (100 g)
Meat cold cuts, regular and light 1 slice (15 g)
Sausage-style cold cuts, regular and light 1 slice (15 g)
Processed cheeses
With different fat contents: 1 tablespoon or
>24%, 20-24%, 9-19%, and 9% one individually packed slice (15 g)
Cola beverages
Regular and light One glass (200 ml)
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measurement should be done in all subjects at the same time phase (O’Leary
and Bots 2008, Holewijn et al. 2010).
Here, IMT was measured from a 1-cm sample from the bifurcation (bulb) with
an 8- or 10-mHz linear array transducer by three experienced sonographers. The
software measured the far wall thickness bilaterally for the 1-cm segment. The
measurement was carried out on the left and right carotid in duplicate with the
C
Figure 7. Above: Ultrasound image of carotid artery. Intima-media
thickness (IMT) is commonly measured 10 mm left of bifurcation. Left from
A = internal carotid artery, B = bifurcation (bulb), C = common carotid
artery (adapted from Lorenz et al. (2007)).
Below: Illustration of a carotid artery (with permission of O. Raitakari).
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subject in a supine position (Stein et al. 2008). The mean intima-media complex
thickness was automatically calculated in micrometers in diastolic phase scans.
The averages of these four measurements were used in the analyses.
Repeatability of the measurements was ensured by rescanning 18 participants
within one week of the first IMT scanning. In addition, cIMT of 15 participants
was measured by two sonographers. The coefficients of variation between the
measurements obtained by the same sonographer (intra CV%) and between
measurements obtained by different sonographers (inter CV%) are shown in
Table 10. Systolic and diastolic blood pressures were measured after the IMT
measurement in supine position in duplicate by an automatic device (Omron
MIT Elite Digital Automatic Blood Pressure Monitor, OMRON Healthcare
Europe B.V., Hoofddorp, the Netherlands), and the second result was used in
the analyses. Pulse pressure was calculated as systolic – diastolic.
4.2.3.3. Laboratory analyses
Twelve-hour fasting blood samples were collected between 7:30 am and 9:15
am  during  the  first  visit.  For  serum  samples,  Venoject  gel  tubes  and  for
plasma/whole blood EDTA tubes were used. Serum/plasma was extracted from
blood (except whole-blood samples) by centrifugation at 3000 rpm for 15 min
within  half  an  hour  after  sampling  and  stored  immediately  after  sampling  at  -
20°C to -70°C until analysis. The samples were collected in the morning due to
the  circadian  rhythm  of  Pi  and  its  metabolites  (Calvo  et  al.  1991)  as  well  as
during  wintertime  to  avoid  the  effects  of  sunlight  on  serum  25(OH)D
concentrations (Lamberg-Allardt et al. 1983).
Table 10 describes the assessments carried out, the devices and methods used,
and the inter and intra CV%’s.  LDL-C/high-density lipoprotein cholesterol
(HDL-C) ratio was calculated as LDL-C/HDL-C. eGFR was determined by
using  the  Cockroft-Gault  formula  (Poggio  et  al.  2005).  All  analyses  were
conducted at the Laboratory of Nutrition, at the Department of Food and
Environmental Sciences.
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4.2.3.4. Final sample
IMT and food intake data were successfully collected from 627 persons. Of
these, postmenopausal females (n=41, data collected by a questionnaire) were
excluded from the analyses, as were persons with moderate renal dysfunction
(estimated glomerular filtration rate, eGFR<60 ml/min) (n=21). In addition, 19
persons were excluded because they did not complete the study due to lack of
Table 10. Inter and intra coefficients of variation percentages (inter CV%; intra CV%) of the
laboratory analyses and IMT measurements.
Assessment Device Method inter CV% intra CV%
S-Total cholesterol Konelab20 1 photometric 4.6 4.6
S-HDL-C Konelab20 1 photometric 4.6 4.6
S-LDL-C Konelab20 1 photometric 4.6 4.6
S-Triglycerides Konelab20 1 photometric 4.6 4.6
S-Creatinine Konelab20 1 photometric 4.6 4.6
S-Glucose Konelab20 1 photometric 4.6 4.6
S-hs-CRP Konelab20 1 photometric 4.6 4.6
S-Calcium Konelab20 1 photometric 4.6 4.6
S-Phosphate Konelab20 1 photometric 4.6 4.6
HbA1c% Konelab20 1 photometric 4.6 4.6
S-25(OH)D* IDS Kit 2 enzyme immuno assay 2.7 3.2
S-iPTH Immulite1000 3 immunolumisnescence 8 <5.5
S-Insulin Immulite1000 3 immunolumisnescence <4.9 <6.2
P-FGF-23 Immutopics kit 4 enzyme-linked immuno assay <5.5 <7.7
IMT MyLab30Gold 5 ultrasound 9.2 6.6
*reproducibility ensured by Vitamin D External Quality Assessment Scheme (DEQAS)
HDL-C high density lipoprotein cholesterol; LDL-C low density lipoprotein cholesterol; hs-CRP high sensitive C-reactive
protein; HbA1c% glycosylated haemoglobin; 25(OH)D 25-hydroxy vitamin D;  iPTH intact parathyroid hormone;
FGF23 fibroblast growth factor 23; IMT intima-media thickness
5  Esaote MyLab30Gold, Firenze, Italy
1  Thermo Clinical Labsystems, Espoo, Finland
2  Immunodiagnostics Systems Ltd., Boldon, UK
3  Siemens Healthcare Diagnostics, Malvern, PA, USA
4  Immutopics INC., San Clemente, CA, USA
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background data or non-fasting blood samples. The final analyses included 370
females and 176 males for whom full nutrition, IMT, background, and
biomarker data were available. Sampling and study protocol are shown in
Figure 9.
Figure 9. Flow-chart of sampling and protocol of Study III. IMT= intima-
media thickness, eGFR=estimated glomerular filtration rate, FFQ=food
frequency questionnaire, F=female, M=male.
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4.2.3.5. Statistical analyses
The power of the study (80%, α=0.05) was calculated basing on the primary
variable of the main study, to find a 4% difference in forearm bone mineral
density between the highest and lowest P intake tertiles. 800 subjects (400
females, 400 males) were expected to participate. Thus, taking into account the
estimated initial drop-out rate of 40%, 720 subjects were invited to the first
sampling. However, the drop-out rate was higher than expected (about 60%)
and to the second sampling 1200 subjects were invited to ensure sufficient
power of the study including the drop out rate during the study. For IMT
analyses no power calculations were performed due to lack of reference values.
Statistical analysis was performed using PASW Statistics version 18.0.2 (IBM,
Armonk, NY, USA). The normality and homogeneity of the data were verified.
Equality of the variances in quintiles and FAP groups was assessed by Levene’s
test.
Correlations  among  IMT,  TP,  P  density  of  the  diet,  and  FAP  intake  and
potential confounding factors were assessed by Pearson correlation coefficients
(data not shown). The covariates were chosen depending on their correlation
with IMT and P intake and their contextual significance. Highly intercorrelated
(r>0.2) confounding factors were not used in the same models. Due to the high
correlation between Ca and P intake, Ca was excluded from the covariates. BMI
correlated with IMT, TP intake, and almost all potential covariates, and thus,
BMI was also excluded from the covariates. Serum LDL-C/HDL-C ratio was
used because it predicts IMT progression better than HDL-C or LDL-C alone
(Enomoto et al. 2011). IMT scanning results of one sonographer differed
significantly  from  the  others;  thus,  sonographer  class  was  coded  as  a  dummy
variable (0 for non-differing sonographer, 1 for differing sonographer) and used
as a random factor in ANCOVA. Smoking status was also coded as dummy (0
for never-smoker, 1 for former or current smoker). The final covariates were
sex  (when  analyzing  all  subjects),  age,  smoking  status,  LDL-C/HDL-C  ratio,
and IMT sonographer as a random factor. Pulse pressure was also included in
some models,  but this did not strengthen the results (data not shown).  P value
less than 0.05 was considered statistically significant.
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Differences  between  quintiles  of  TP  intake/P  density  of  the  diet  and  six  FAP
groups, considering potential confounding factors, were assessed by analysis of
variance (ANOVA, unadjusted for covariates). ANCOVA was used to analyze
differences  in  IMT  between  quintiles  of  TP/P  density  of  the  diet  and  FAP
groups. Especially under interest was to determine whether high TP/P density
of the diet/ FAP intake is associated with higher IMT, or are there differences in
IMT between high and low P intake. Tests for significant linear trends in
associations between P variable intakes and IMT were performed by contrast
analysis.
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5. Results
5.1.  Study I
5.1.1. Usefulness of the method for analysis of in vitro digestible
phosphorus
In the DP analysis, the mean P content of the unofficial in-house white wheat
flour reference samples (n=32) was 49.7 mg P/100 g (SD 9.0 mg). Due to the
newness of the analysis method, no earlier results of DP content in the reference
material were available and these results only estimate the repeatability of the
method. The accuracy and precision of the TP analysis was tested by a certified
reference sample (NIST 1567a, wheat flour, n=10) and by an unofficial inhouse
wheat flour reference sample (n=10). The mean values (±SD) for the references
were 133.4±8.6 mg P/100 g and 342.7±8.6 mg P/100 g, respectively. The NIST
1567a value was in accordance with the certified range (134±6 mg P/100 g)
analyzed by a standard methodology (National Institute of Standards and
Technology) by the manufacturer and acceptable (361±8 mg P/100 g) for the
in-house reference (Saari and Paaso 1980). For the P analysis by ICP-MS, the
limit of detection was 0.3 mg/l and the limit of quantitation 3 mg/l (equivalent
to 60 mg/kg in the original sample). The values were based on 14 standard
blanks and were calculated as 3*SD and 10*SD of the standard blank,
respectively. The quantitation was made by using external calibration with 5
points between 0 and 2000 mg/l. The curve type linear through zero was used.
The typical correlation factor of the standard curve was 0.99999 and the linear
measurement range was from 0 mg/l to 6000 mg/l. The calculated uncertainty
for the in vitro DP analysis was 7.4%, and for the TP analysis 6.4%.
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5.1.2. In vitro digestible and total phosphorus contents in differently
processed cereals
The  absolute  values  of  DP  and  TP  contents  in  analyzed  foodstuffs  within
measurement uncertainty are shown in Appendix, Table 3. In rye samples, TP
content was higher in rye flour than in rye breads (Figure 10A). In rye breads
the percentage DP relative to TP was similar (68–78%) in all breads analyzed.
Differences between the DP contents of home-baked and bakery breads were
not  significant  (p>0.05).  The  amount  of  DP  in  the  rye  sourdough  was  almost
100%, indicating that some of DP has become insoluble in the baking process,
when comparing to the DP contents which were lower in bread. The high DP
amount in dough can also be explained by the measurement uncertainty. Figure
10B shows DP contents in rye dough and bread originating from 100 g of flour.
When the results of DP in dough and bread originating from 100 g of flour were
tested by paired t-test, the differences were significant (p<0.001) between all
pairs compared (flour-dough, flour-bread, dough-bread).
In wheat samples,  DP content was 46–51% of TP in wheat breads,  56–83% in
doughs, and 43% in flour (Figure 11A). The analyzed non-soured wheat cereals
contained lower percentages of DP than soured cereals. Figure 11B shows DP
contents in wheat dough and bread originating from 100 g of flour. When DP
contents in dough and bread originating from 100 g of flour were compared by
paired t-test, the differences were significant (p<0.001) between all pairs
compared (flour–dough, flour–bread, dough–bread), except for wheat flour –
non-soured bread (p=0.158). In wheat flour – non-soured dough, the differences
were also significant (p=0.002). However, DP, as well TP contents in wheat
products were lower than in rye samples.
In processing of barley, the 3-h baking time degraded the phytate in large
amounts and increased the DP content from 29% in grits to 69% in porridge
(p<0.001) (Figure 12A). Figure 12B shows DP contents in barley products
considering the grits used for 100 g of porridge; there was an almost 2.5-fold
increase in the DP contents. Like in wheat samples, the DP and TP contents in
barley samples were lower than in rye samples.
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Figure 10. Panel A: Total and digestible phosphorus contents in analyzed rye products. Error bars show standard
deviation. Percentages indicate digestible phosphorus/total phosphorus. TP total phosphorus = DP digestible
phosphorus; HB = home-baked bread; B-WP bread  = bakery bread also containing wheat and potato; B-WR bread
= bakery whole rye bread.
Panel B: Digestible phosphorus contents in rye products considering the amount of dough and bread originating
from 100 g of flour.
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Figure 11. Panel A: Total and digestible phosphorus contents in analyzed wheat products. Error bars show standard
deviation. Percentages indicate digestible phosphorus/total phosphorus. TP = total phosphorus; DP = digestible
phosphorus; US dough = unsoured dough; US bread = unsoured bread; S dough = soured dough; S bread = soured
bread; B bread = bakery bread.
Panel B: Digestible phosphorus contents in wheat products considering the amount of dough and bread originating
from 100 g of flour.
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Figure 12. Panel A: Total and digestible phosphorus contents in analyzed barley products. Error bars show
standard deviation. Percentages indicate digestible phosphorus/total phosphorus. TP = total phosphorus; DP =
digestible phosphorus.
Panel B: Digestible phosphorus contents in barley products considering the grits used for 100 g porridge.
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5.2. Study II
5.2.1. In vitro digestible and total phosphorus contents in the analyzed
plant-based foodstuffs
Table  11  presents  the  TP  and  DP  contents  of  analyzed  plant  foods
(Section A: Bakery products, Section B: Legumes and seeds, Section C:
Beverages). Percentages of DP/TP contents are shown in Figure 13.
The highest P contents were found in rye crisp (TP 291 mg/100 g; DP 191
mg/100 g) (Table 11A). The TP contents of all other breads, except in rye
crisp, were similar (189-208 mg/100 g), but DP contents of the breads
varied more (54-123 mg/100 g).  Some differences were found in DP
contents between two very similar small rye breads containing potato (89
vs. 54 mg/100 g). FAP-containing muffins had relatively high contents of
both TP (212 mg/100 g) and DP (201 mg/100 g), as well the percentages
of DP (Figure 13). Cookies and sweet buns had lower TP and DP contents
than muffins (116-125 mg/100 g TP, 43-60 mg/100 g DP, respectively).
TP contents among the analyzed legume and seed products varied
between 57 (green beans) and 667 mg/100 g (sesame seeds) (Table 11B).
The lowest DP content was found in green bean (24 mg/100 g), which
had, however, the highest percentage of DP (42%). Apparently, the
lowest percentage of DP/TP was present in sesame seeds (6%) (Figure
13).
DP and TP contents in all  cola beverages and beer were of lowest of the
foods  analyzed  in  this  study  (Table  11C).  Almost  all  of  the  P  in  these
beverages was in vitro digestible P (beer 22 mg/100 g, colas 10-16
mg/100 g). The percentages of DP for some beverages exceeded 100%,
probably due to the inaccuracy of the analysis method with regard to low
P contents (Table 11C). FAP-containing cola drinks had high percentages
of DP.
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Table 11. Total phosphorus (TP) and in vitro digestible phosphorus (DP)
contents of the analyzed plant foods.
Product TP (mg/100 g) DP (mg/100 g)
A: Bakery products
Rye bread pool 208 123
Rye crisp 291 191
Small rye bread containing potato 1 192 89
Small rye bread containing potato 2 206 54
Mixed grain bread with seeds 189 116
Muffin poola 212 201
Sweet bun pool 116 60
Cookie pool 125 43
B: Legumes and seeds
Sesame seed (with hull) 667 42
Tofu (firm) 164 51
Green bean 57 24
Green pea (frozen) 118 50
Chickpea (soaked) 149 53
Red lentil 432 167
Green lentil 400 120
C: Beverages
Pepsi Maxb 14 15
Coca-Cola lightb 13 13
Coca-Colab 19 16
Cola poolb 17 16
Freeway Cola lightb 11 10
Beer 21 22
a Contains sodium polyphosphate as an additive
b Contains phosphoric acid as an additive
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Figure 13. Percentages of in vitro digestible phosphorus (P) to total P in
analyzed plant-based foods.
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5.3. Study III
5.3.1. Characteristics of subjects
The study population was 37-to-47-year old, slightly overweight, and
normotensive. Two-third were females, half of the population was current
or earlier smokers. The subjects were to some extent
hypercholesterolemic, otherwise healthy considering the assessed
biomarkers (Tables 12 and 13). The nutrient intakes were according to the
recommendations; however, the mean P intake exceeded the
recommendations (Table 12).
Table 12.  Background and nutrient intake data of study subjects. Values are presented as mean ± SD.
Variable All Females Males
(n=546) (n=370) (n=176)
Background data
Intima-media thickness (µm) 552 ± 69 544 ± 70 567 ± 66
Body mass index (kg/m 2) 26.8 ± 4.9 26.6 ± 5.2 27.2 ± 3.9
Age (years) 41.9 ± 2.8 41.9 ± 2.7 42.1 ± 3
Sex (% females) 67 ± 47 -
Current or former smoker (%) 48 ± 50 45 ± 50 55 ± 50
Systolic blood pressure (mmHg) 125 ± 14 122 ± 14 129 ± 13
Diastolic blood pressure (mmHg) 77 ± 11 76 ± 11 80 ± 11
Pulse pressure (mmHg) 48 ± 6 47 ± 6 50 ± 6
All physical activity (mins/week) 479 ± 380 515 ± 397 406 ± 332
Nutrient intake data
Energy intake (kJ/d) 8413 ± 1994 7944 ± 1807 9398 ± 2014
Fat intake (g/d) 80 ± 26 76 ± 26 88 ± 25
Saturated fat intake (g/d) 29 ± 11 28 ± 11 32 ± 11
Phosphorus intake (mg/d) 1617 ± 428 1532 ± 378 1795 ± 469
Calcium intake (mg/d) * 1199 ± 453 1195 ± 435 1207 ± 489
Vitamin D intake ( µ g/d) * 9.1 ± 8.6 9.4 ± 9.3 8.4 ± 6.8
Phosphorus density of the diet (mg/MJ/d) 194 ± 36 195 ± 37 192 ± 34
FAP intake score 3.2 ± 1.4 3.1 ± 1.3 3.6 ± 1.4
* supplements included; FAP=food additive phosphate
100
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The correlations between IMT, P intake, P density of the diet, and FAP
intake, and potential confounding factors were assessed to define the
covariates for the ANCOVA analysis (data not shown). Further, subjects
were divided into quintiles (FAP intake; six groups) to find out the
differences between those groups concerning the regulators of P
metabolism; particular attention was paid to S-Pi, P-FGF23, S-iPTH, and
S-25(OH)D concentrations as well as to Ca:P intake ratios (ANOVA,
unadjusted for covariates). These analyses were only performed for all
subjects.  Quintile/group  sizes  and  P  intakes,  P  densities  of  the  diet,  and
FAP intakes scores are described in Table 14.
Table 13. Biomarker data of study subjects. Values are presented as mean ± SD.
Variable All Females             Males
(n=546)            (n=176)
S-Pi (mmol/l) 1.09 ± 0.15 1.1 ± 0.15 1.06 ± 0.16
S-Ca (mmol/l) a 2.09 ± 0.07 2.09 ± 0.07 2.1 ± 0.07
P-FGF-23, C-terminal (RU/ml) 78.5 ± 84.7 85.1 ± 101.7 64.9 ± 20.1
S-PTH (pg/ml) 55 ± 25.2 56.9 ± 26 51 ± 23
S-25(OH)D (nmol/l) 55.4 ± 19.5 56.4 ± 20 53.4 ± 18.3
S-Total cholesterol (mmol/l) 5.45 ± 0.9 5.29 ± 0.84 5.77 ± 0.93
S-HDL-C (mmol/l) 1.51 ± 0.4 1.61 ± 0.39 1.33 ± 0.37
S-LDL-C (mmol/l) 2.94 ± 0.79 2.75 ± 0.72 3.34 ± 0.79
LDL-HDL ratio 2.13 ± 0.94 1.85 ± 0.77 2.71 ± 0.98
S-Triglycerides (mmol/l) 1.3 ± 0.73 1.14 ± 0.61 1.62 ± 0.86
eGFR (ml/min) 91.5 ± 20.9 85.6 ± 19.5 103.5 ± 18.6
S-HS-CRP (mg/l) 2.07 ± 4.47 2.13 ± 4.22 1.93 ± 4.97
S-Glucose (mmol/l) 5.08 ± 0.6 5 ± 0.48 5.24 ± 0.78
HbA1c % 5.06 ± 0.26 5.04 ± 0.24 5.11 ± 0.28
S=serum; P=plasma; Pi = phosphate; Ca = calcium; FGF-23 = fibroblast growth factor 23; PTH = parathyroid hormone;
PTH = parathyroid hormone; 25(OH)D = 25-hydroxy vitamin D; HDL-C = high-density lipoprotein cholesterol;
LDL-C = low-density lipoprotein cholesterol; eGFR = estimated glomerular filtration rate; HS-CRP = high-sensitivity
C-reactive protein; HbA1c % = glycosylated hemoglobin (% of total hemoglobin) a adjusted for albumin
(n=370)
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No significant differences in S-Pi (p=0.739), P-FGF-23 (p=0.511), S-
iPTH (p=0.173), or S-25(OH)D (p=0.073) concentrations emerged
between TP quintiles. Ca:P ratios between quintiles differed almost
significantly  with  a  tendency  towards  higher  Ca:P  ratio  with  higher  TP
intake (p=0.059). S-Pi and P-FGF-23 concentrations did not differ
significantly across P density quintiles (p=0.731 and p=0.187,
respectively). S-iPTH concentrations were lower (p=0.045) and S-
25(OH)D concentrations higher (p=0.004) with higher P density. Ca:P
ratios were lower with lower P density (p=0.018). Between FAP groups,
no significant differences emerged in P-FGF-23 (p=0.499), S-iPTH
(p=0.313), S-25(OH)D concentrations (p=0.418), or Ca:P ratios
Table 14.  Quintile/group sizes and ranges of P intakes, P densities of diet, and FAP intakes scores in quintiles/groups.
1st 2nd 3rd 4th 5th 6th
All subjects (n) 109 109 109 109 110 -
P intake (mg/d) 0-1272 1273-1462 1463-1665 1666-1962 1963-3205 -
Females (n) 74 74 75 73 74 -
P intake (mg/d) 0-1232.7 1233-1390 1391-1563 1564-1795 1796-2800 -
Males (n) 34 35 35 36 35 -
P intake (mg/d) 0-1443 1444-1610 1611-1850 1851-2163.9 2164.0-3205 -
All subjects (n) 109 109 109 109 110 -
P density of diet (mg/MJ/d) 0-162.1 162.2-182.8 182.9-200.85 200.86-222.1 222.2-320 -
Females (n) 74 74 75 73 74 -
P density of diet (mg/MJ/d) 0-164.5 164.6-183.0 183.1-203.0 203.1-224.0 224.1-310 -
Males (n) 35 35 35 36 35 -
P density of diet (mg/MJ/d) 0-160 161-182 183-198 199-218.0 218.1-320 -
All subjects (n) 66 111 151 109 85 29
FAP score 1 2 3 4 5 6
Females (n) 45 77 101 73 55 20
FAP score 1 2 3 4 5 6
Males (n) 16 39 54 28 33 10
FAP score 1 2 3 4 5 6
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(p=0.266), but S-Pi concentrations were negatively associated with FAP
intake (p=0.006).
5.3.2. Associations between phosphorus intake variables and carotid
intima-media thickness
Total phosphorus intake
No significant association was found between TP intake and IMT (for all
p=0.233, for females p=0.293, ANCOVA adjusted for sex [when
analyzing  all  subjects],  age,  LDL-C/HDL-C  ratio,  smoking  status,  and
IMT sonographer class) (Figure 14). Neither was there any linear trend in
associations between TP intake and IMT among all subjects (p=0.136,
contrast analysis), but among females an almost significant positive linear
trend was present (p=0.072, contrast analysis), and the 1st and  5th intake
quintiles differed significantly (p=0.035). No significant differences were
found among males (p>0.05).
Figure 14. Mean carotid intima-media thickness (IMT) with upper limit
of 95% confidence interval in TOTAL PHOSPHORUS (TP) intake
quintiles for ALL SUBJECTS (WHITE SCALE, p for all 0.233,
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ANCOVA), for FEMALES (GRAY SCALE, p for all 0.293, ANCOVA)
and for MALES (BLACK SCALE, p for all 0.719, ANCOVA).
Statistically significant differences from the highest TP intake quintile
(ANCOVA) are shown with an asterisk (* p<0.05) (between all other
groups p>0.05).
Phosphorus density of the diet
No significant association existed between P density of the diet and IMT
(for all p=0.289, for females p=0.231, ANCOVA adjusted for sex [when
analyzing  all  subjects],  age,  LDL-C/HDL-C  ratio,  smoking  status,  and
IMT sonographer class) (Figure 15). However, in between-quintile
comparison among all subjects the 1st and  5th intake quintiles differed
almost significantly (p=0.064), and among females, the 1st quintile
differed almost significantly (p=0.065) and the 2nd quintile differed
significantly (p=0.034) from the 5th quintile  in  IMT.  Furthermore,  a
significant positive linear trend occurred between P density of the diet and
IMT among all subjects (p=0.039, contrast analysis), and among females
an almost significant positive linear trend was present (p=0.067, contrast
analysis). No significant differences were found among males (p>0.05).
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Figure 15. Mean carotid intima-media thickness (IMT) with upper limit
of 95% confidence interval in P density quintiles for ALL SUBJECTS
(WHITE SCALE,  p for all 0.289, ANCOVA), for FEMALES (GRAY
SCALE, p for all 0.231, ANCOVA), and for MALES (BLACK SCALE, p
for all 0.432, ANCOVA). Significant differences from the highest P
density quintile (ANCOVA) / statistically significant trends (contrast
analysis) between P density and IMT are indicated with asterisks
(*p<0.05) (between all other groups p>0.05).
Food additive phosphate intake
The population was divided into six groups based on FAP intake scores.
No significant association between FAP intake and IMT was observed
(for all p=0.097, for females p=0.267, ANCOVA adjusted for sex [when
analyzing  all  subjects],  age,  LDL-C/HDL-C  ratio,  smoking  status,  and
IMT sonographer class) (Figure 16). Nevertheless, comparison of the
intake groups revealed that among all subjects, IMT was higher with
higher FAP intake, and the 6th intake group differed significantly from
almost all other groups (1st p=0.009, 2nd p=0.032, 3rd p=0.052, 4th p=0.006,
P density quintile
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5th p=0.038);  this  was  also  the  case  among  females  (1st p=0.037, 2nd
p=0.045, 3rd p=0.086, 4th p=0.019, 5th p=0.113). In addition, a significant
positive linear trend existed between FAP intake and IMT among all
subjects (p=0.022, contrast analysis) and among females (p=0.045,
contrast analysis). Among males, no significant differences were found
(p>0.05).
Figure 16. Mean carotid intima-media thickness (IMT) with upper limit
of 95% confidence interval in FOOD ADDITIVE PHOSPHATE (FAP)
intake groups for ALL SUBJECTS (WHITE SCALE, p for all 0.097,
ANCOVA), for FEMALES (GRAY SCALE, p for all 0.267, ANCOVA),
and for MALES (BLACK SCALE, p for all 0.372, ANCOVA).
Statistically significant differences from the highest FAP intake group
(ANCOVA) / statistically significant trends (contrast analysis) between
FAP intake and IMT are indicated with asterisks (*p<0.05, **p<0.01)
(between all other groups p>0.05).
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6. Discussion
6.1. Bioavailability of phosphorus in foodstuffs
6.1.1. Reliability of the analysis method for in vitro digestible
phosphorus
According to measurement uncertainty calculation, the analysis method
for in vitro digestible P seems to be trustworthy. The method originally
developed by Asp et al. (1983) for the analysis of dietary fiber was later
modified by Ekholm et al. (2000, 2003). Here, some modifications for the
determination of DP were made. The rationale of the method was to
mimic the processing of foodstuffs in the alimentary tract using
alimentary enzymes with changes in pH and processing temperatures.
Based on the calculations, the impact of measurement uncertainty on the
DP results was 7.4%. In Study II, the proportion of DP in some foodstuffs
exceeded 100%, which may be explained by the measurement uncertainty.
However, in vitro methods only yield suggestive information on
bioavailability, since the interaction between alimentary tract and food
cannot be measured, neither the circulation exists (Sandberg 2005). This
naturally increases the uncertainty in the in vitro results and limits the
extrapolation of these results to in vivo circumstances, and thus,
validation in vivo is needed (Miller and Berner 1989).
6.1.2. Effect of processing on in vitro digestible and total phosphorus
contents in cereals
In the present study, different rye breads were found to have similar
proportions of DP (68-78 %), while in rye dough, the proportion of DP
was almost 100%. In some earlier studies, the phytic acid content in rye
bread was almost reduced to zero during processing (Larsson and
Sandberg 1991, Fretzdorff and Brümmer 1992), which probably also
87
occurred in our study, but during baking of rye bread some P of dough
may have become insoluble for unknown reasons, because he DP contents
in bread were lower than in dough.
The results resemble those of previous studies in which phytates were
mostly degraded in sourdough rye bread (Plaami and Kumpulainen 1995),
and are also compatible with Karp et al. (2007) study, who found that the
intake of unfermented cereals did not increase S-Pi concentration
compared with other P sources, such as cheese and meat, indicating a
lower bioavailability of P in cereals. Here, the bakery breads did not
seemingly differ in P contents compared with home-baked bread, even
though they might not have been leavened for as long time as home-
baked breads. Rye bread in Finland is prepared by fermenting the dough,
traditionally without yeast.  However, exact information about
fermentation times of the bakery products is not available. When
compared to other analyzed cereals, the TP contents in flour were much
higher (about 300 mg/100g) than in doughs or breads, which, however, is
logical because doughs and breads also contain ingredients besides flour.
TP contents in wheat samples were lower than in rye products because
also fiber and whole-grain contents were lower. In the studied wheat
samples, the mean proportion of DP was about 50%, and it increased with
processing especially in soured wheat bread. As shown in t-test,
significant differences were present between flour-dough, flour-bread,
and dough-bread pairs, except for flour-unsoured dough pair. Naturally,
wheat flour had the highest contents of total P (about 110 mg/100 g)
because no water or other ingredients were added as in doughs and breads.
When comparing the amounts of DP in dough and bread originating from
100 g of flour, DP in wheat sourdough and soured wheat bread increased
significantly relative to flour or unsoured dough and bread. The soured
wheat  bread  contained  a  small  amount  of  rye  sourdough,  but  it  likewise
seemed not to affect the results, although souring is known to decrease
phytic acid content (le Francois 1988), while in a previous study adding
of rye sourdough increased phytic acid hydrolysis in oat-containing
doughs (Larsson and Sandberg 1991). These results support the studies of
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Reale et al. (2004), in which the fermentation time of yeast-containing
bread was not long enough to degrade phytates: neither changes in DP
contents between flour and yeast-fermented dough were seen here. The
added amount of yeast was probably too low to cause an increase in the
DP content of the breads, although yeast contains a small amount of
phytase (Türk et al. 1996).
Barley porridge, which was baked in the oven for three hours, contained a
much higher percentage of DP than barley grits, indicating that a long
hydrothermal processing causes degradation of phytate and thus,
increases inorganic, digestible P contents (Sandberg 2002). The DP
content in that amount of barley grits needed for 100 g porridge was more
than double when comparing to the original DP content of grits.
Nevertheless, one must take into account that barley porridge is usually
made with milk, which includes Ca. Ca prevents phytate degradation, at
least in doughs (Türk and Sandberg 1992), and milk also contains P,
which would also affect the results. Thus, the results of milk-based
porridge would probably be different.
 6.1.3. In vitro digestible and total phosphorus contents in other plant-
based foodstuffs
Both TP and DP contents varied widely in food groups analyzed. Protein
content mainly explains the differences in TP contents in regular products,
but the proportion of DP can be affected by food processing in food
containing phytic acid (as seen in Study I), or by the use of P-containing
food additives. In cereals, seeds, and legumes, phytate-derived P accounts
for  the  majority  of  TP  (Reddy  2002),  but  it  needs  to  be  hydrolyzed  to
release inorganic Pi in a form available for absorption in the body.
Although phytase activity in human gut is very low (Iqbal et al. 1994),
different food processing methods can hydrolyze phytic acid (Plaami
1997). Thus, more P is likely to be digestible from processed (i.e.
fermented, soaked) plant-derived foodstuffs than from raw or unprocessed
foods.
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Of the sweet bakery products, sweet buns (leavened with yeast) and
cookies  (containing  no  FAPs)  had  a  P  content  similar  to  that  in  white
wheat bread (analyzed in Study I). However, industrially prepared
muffins containing FAP (baking powder) differed from other wheat
products; the percentage of DP was almost 100%. TP content of muffins
was similar to that of rye bread, but DP content was higher than in any
breads.  An  average  muffin  and  sweet  bun  both  weight  about  50  g;  if  a
muffin with FAP is chosen, the amount of DP is 100 mg, but if the yeast-
leavened sweet bun was chosen, the amount of DP is only 30 mg.
Therefore, persons who consume large amounts of FAP-containing
bakery products may ingest substantial amounts of bioavailable P.
Of  the  foods  analyzed  in  this  study,  the  proportion  of  DP  from  TP  was
lowest  in  legumes  and  seeds  (6-42%  of  TP).  Earlier  results  have
suggested that bioavailability of P in beans is only 25% (Uribarri 2007).
Findings of the current study, by contrast, indicate DP contents in
legumes to be on average higher than this. However, similarly to lentils,
beans, and peas, sesame seeds with hull had a low DP content (42 mg/100
g). This is in line with the results of an earlier short-term controlled study,
where whole sesame seeds did not affect the concentrations of S-Pi
indicating  them  to  be  poor  sources  of  bioavailable  P  (Kärkkäinen  et  al.
1997).  Nevertheless, the cooking time of lentils, green beans, and peas is
relatively short, and these products do not require soaking before cooking
(except dry peas), which would decrease phytate contents and release
inorganic Pi (Sandberg 2002). Thus, it is unlikely that a large proportion
of phytate is hydrolyzed during processing, and therefore, DP content in
lentils, green beans, and peas would not rise notably, if at all, when these
products are cooked. Nevertheless, to evaluate the bioavailable P in
legumes requiring long soaking and cooking times (such as soy beans and
chick peas), more analyses of the effects of processing on DP contents are
needed.
In beer and cola beverages, all P was digestible. This result is in line with
previous  results  on  high  absorbability  of  P  from  food  additives  such  as
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phosphoric acid in cola drinks which appears to absorb completely in the
intestine  (Bell  et  al.  1977,  Karp  et  al.  2007).  TP  contents  in  both  cola
drinks and beer were comparable with values published earlier (Murphy-
Gutekunst 2005, Institution for Health and Welfare 2011). In beer, P
originates from the grain used in preparing the product; in Finland, this is
most often barley. Based on these results, it seems that during malting and
other processing of grain when preparing beer, P is efficiently released
from the grain to a highly digestible form, resulting in a high proportion
of DP. Processing of beer also includes fermentation with yeast, which is
known to contain phytase, and thus, the ability to degrade phytate to
bioavailable  P  (Türk  et  al.  2006).  However,  in  beer,  as  in  some  cola
beverages  the  amount  of  DP  exceeded  the  amount  of  TP.  This  may  be
explained by the uncertainty of the analysis method under circumstances
of low P content; the calculated measurement uncertainty for the DP
analysis method in Study I was 7.4%. Thus, at small concentrations of DP
(beer 22 mg/100g, colas 10-16 mg/100g), a 1-2 mg change within the DP
contents can be explained by the variability of the method. Nevertheless,
even though the amounts of P in these beverages are not very high,
persons consuming beer or cola drinks in abundance may ingest a
considerable amount of DP in these drinks. This may be important
because replacing milk (containing Ca and natural P) with cola beverages
and increasing beverage consumption in the general population can have
adverse effects on Ca and bone metabolism (Fernando et al. 1999,
Kristensen et al. 2005, Tucker et al. 2006).
Based  on  the  results  of  Studies  I  and  II, in vitro DP content in different
rye breads can vary substantially, most likely depending on the amount
and proportion of rye flour and crushed rye grain, the content of other
grains or potato, the use of yeast, and the length of fermentation (Türk et
al. 1996, Sathe and Venkatachalan 2002). Further, the grounding stage of
the flour generally results in differences in P contents; DP content of
white wheat bread analyzed in Study I was lower than DP content of rye
or mixed-grain bread in Study II. In practice, the differences in the
amounts of P from foodstuffs can easily be demonstrated by calculating
regular  portions  of  P  in  DP and  TP.  If  one  person  eats  5  slices  of  bread
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(here: small rye bread containing potato 1 from Study II, 33 g/each) per
day, the amount of P intake varies markedly depending on whether
calculated by TP or DP; TP from bread is 317 mg, and DP is 147 mg. The
amount of P calculated as TP is double that of DP. If the same amount of
white  wheat  bread  (Study  I)  is  chosen,  the  amount  of  TP  would  be  136
mg, and DP 70 mg. This shows that depending on the calculation method
to take into account TP or DP, P intake can vary widely. At least in CKD
patients, this may be relevant because in practice they must follow a P-
restricted diet and food choices can have a real effect on P intake and
diversity of the diet. However, use of different porridges made of flakes
(oat, rye, mixed cereals) is also common in Finland (Helldán et al. 2013b),
and analysis of their DP contents should be considered.
6.1.4. Conclusions about phosphorus bioavailability in analyzed
foodstuffs
The in vitro DP content in processed cereals was less than the in
unprocessed cereals, confirming the hypothesis. This is probably because
during processing of foodstuffs phytate was degraded to lower inositol
Pi’s and the same process formed inorganic Pi, which increased the DP
content (Sandberg 2002). The products were processed under
circumstances where both enzymatic and non-enzymatic degradation can
occur (low pH, high temperature, presence of yeast, hydrothermal
processing) (Sandberg 2002, Sandberg and Andlid 2002); some of the
doughs were soured and some were leavened with yeast and baked which
should increase the inorganic Pi contents.
DP contents among other studied plant-based foodstuffs seemed to differ
substantially  among  different  foodstuffs.  Despite  high  TP  content,
legumes  and  seeds  may  be  relatively  poor  P  sources  of  bioavailable  P.
Results support previous understanding of the effective absorbability of P
from P additives. Bakery products containing baking powder may
substantially increase intake of DP. Thus, these bakery products can be an
important source of highly bioavailable, in addition to meat products,
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processed cheeses, and cola beverages.  However, the results of DP
provide only suggestive data on P bioavailability, and thus, should be
confirmed  with  an in vivo method. If DP analysis is proven a valid
method for evaluating P availability, it could be used to estimate the
bioavailability of P in eg. P-restricted diets.
These results indicate that different P sources their bioavailability should
be taken into account more seriously in research on P intake and health
outcomes.  The  original  aim  was  to  use  the  results  of  bioavailable  P
contents of Studies I and II in assessing the associations of dietary P with
CVD risk factors (Study III). This, however, proved to be impossible
because only particular foodstuffs among the thousands included in food
composition databases were analyzed. Nevertheless, in Study III, we were
able to analyze the data concerning both total P sources, and the
potentially more detrimental FAP-containing products.
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6.2. Dietary phosphorus as a potential cardiovascular risk
factor
6.2.1. Total phosphorus intake and cardiovascular health
This study demonstrated that high dietary P intake should be taken into
account as a potential cardiovascular risk factor in the general population.
Positive  linear  trends  in  associations  among  P  density  of  diet  and  IMT
were  found.  IMT  of  females  was  significantly  higher  in  the  highest  TP
intake quintile than in the lowest intake quintile, and an almost significant
linear trend emerged between TP intake and IMT. Here, attention was
paid to TP intake, which, when divided by energy intake describes the P
density of the diet, excluding energy intake as a potential confounding
factor. In the study of Chang et al. (2014a) in particular high P density of
the diet was associated with adverse mortality outcomes. The results
support the hypothesis that in addition to elevated S-Pi concentration, also
higher dietary P intake may be a cardiovascular risk factor in terms of
high IMT in a normal, healthy population. Individuals with low
glomerular filtration rate (eGFR <60 ml/min) were excluded, and thus,
the possible effects of improper kidney function did not affect the results.
Earlier data on health effects of high P intake on the normal population
are scarce, and most studies carried out on P intake have focused on bone
health (Calvo 1993, Kärkkäinen and Lamberg-Allardt 1996, Kemi et al.
2006, 2009, 2010).
The subjects, who participated in the present study, were middle-aged and
on average overweight (mean BMI 26.8 kg/m2). Dietary P intake in study
subjects was slightly higher than the habitual P intake in the national
FINDIET 2012 Study (females 1532 mg/d vs. 1369 mg/d, males 1795
mg/d vs. 1694 mg/d) (Helldán et al. 2013a). While marked variation in TP
intake can be seen between the quintiles (smallest intake quintile ca. 1100
mg/d, and highest ca. 2300 mg/d), on average all subjects exceeded the
recommended intakes (National Nutrition Council 2014). P density of the
diets was similar to mean intakes in the FINDIET 2012 Study (females
94
195 mg/MJ/d vs. 197 mg/MJ/d, males 192 mg/MJ/d vs. 187 mg/MJ/d)
(Helldán et al. 2013a). The mean Ca intake met the recommendations
(National Nutrition Council 2014) and vitamin D intake and the S-
25(OH)D concentrations were satisfactory, especially taking into account
that the study was carried out during the dark season. Thus, the study
population may have had a better Ca balance and nutritional status than
other populations because of the adequate intakes of Ca and vitamin D
(e.g. Welch et al. 2009).
However, human data on dietary P intake and CVD risk factors are
limited. Acute high P intake has decreased endothelial function of the
vessels (Shuto et al. 2009), and high dietary P intake was associated with
left ventricular hypertrophy among women but not among men
(Yamamoto  et  al.  2013).  Recently,  in  the  NHANES  cohort,  dietary  P
intake >1400 mg/d and P density of diet >0.35 mg/kcal (corresponding to
146 mg/MJ) were associated with all-cause mortality, and high P density
(>0.35 mg/kcal) was associated with CVD mortality (Chang et al. 2014a).
In  that  study,  also  low P  density  of  diet  (<0.35  mg/kcal)  was  associated
with increased mortality risk. Notable in these above-mentioned studies is
that the P intakes associated with adverse health effects, are similar to or
lower than the average intakes in Finland (Helldán et al. 2013a). The
NHANES Study produced much discussion about P sources and their
bioavailability (McCarty 2014);  the results of Studies I  and II  contribute
to this discussion.
6.2.2. Food additive phosphorus intake and cardiovascular health
Here, the research question was addressed separately for TP intake and
FAP intake because FAP is more absorbable in the intestine than natural
P (Bell et al. 1977, Karp et al. 2007). As noted in Study II, and consistent
with an in vitro study by Karp et al. (2012), the amounts of DP are higher
in foodstuffs containing FAPs than products without FAPs. As mentioned
earlier,  the contribution of FAP to TP are mainly unknown and amounts
of FAP in foodstuffs vary greatly between manufacturers. In the current
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study, positive linear trends in association between FAP intake and IMT
were found when analyzing all subjects and females.
Previous data on FAP intake are scarce and studies on health outcomes of
FAP are mainly concerned on bone health (Fernando et al. 1999,
Kristensen et al. 2005, Tucker et al. 2006, Karp et al. 2007, Kemi et al.
2009, Karp et al. 2013). In the earlier-mentioned studies on dietary P and
CVD (see Section 6.2.1.), FAP intake data was unavailable. Here, FAP-
containing meat products, processed cheeses, and cola beverages were
included in calculations, and significant differences in IMT emerged
between subjects having high and those having low FAP intake.
Nevertheless, in nutrient values based on food composition databases,
FAPs may not have been taken into account due to the calculated
nutrients values which are not based on chemically analyzed values.
Many studies conclude that TP content in, for example, meat products can
be twice as high as that calculated from the nutritional programs based on
food composition databases, since analyzed data on FAP content is
missing in the current databases (Oenning et al. 1988, Calvo et al. 2014).
This can also uncertainty in results of the current study.
6.2.3. Serum phosphate and other regulators of phosphate
metabolism and cardiovascular health
A few studies have been conducted to assess the associations between
elevated S-Pi concentrations and IMT or vascular calcification, but this
study  is  one  of  the  first  to  investigate  the  association  of  dietary  P  with
IMT.  Ruan  et  al.  (2010)  found  that  even  in  young  persons  S-Pi  was
associated with higher cIMT. Onufrak et al. (2008), in turn, showed that
S-Pi was associated with IMT among males but not among females. In a
Korean study (Park et al. 2010) low S-Pi was associated with less
coronary  calcification,  and  Foley  et  al.  (2009)  found  high  S-Pi  to  be
associated with coronary calcification. Tuttle and Short (2009) showed in
a longitudinal design in adult population that S-Pi concentrations
independently predicted coronary artery calcification. Numerous other
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data  on  association  of  high  S-Pi  and  CVD  risk  also  exist  (Tonelli  et  al.
2005, Dhingra et al. 2007, Foley et al. 2008, Ix et al. 2009, Kendrick et al.
2010, Larsson et al. 2010, Sim et al. 2013), but the findings of Taylor et al.
(2011) showing no association of plasma Pi with development of
coronary heart disease among males are not in accord with the others.
Interestingly,  in the current study, S-Pi was highest  with the lowest FAP
intake scores among all subjects. Earlier cross-sectional studies have
shown that dietary P intake correlates only weakly with S-Pi (Mataix et al.
2006, de Boer et al. (2009). Uribarri (2013) suggests that due to the high
circadian variation of S-Pi and very weak correlation between P intake
and S-Pi in cross-sectional studies, peak S-Pi concentration after oral Pi
load, in addition to mean 24-h S-Pi concentrations, could be better
indicators of potential adverse health effects. Ellam and Chico (2012)
state that high bioavailability of P in Western diets may cause high post-
prandial Pi peaks, and in healthy humans, oral Pi supplementation has
been noted to cause S-Pi to rise to the to upper level of the normal range
(Kärkkäinen and Lamberg-Allardt 1996, Kemi et al. 2006, Karp et al.
2007). However, in our study, we were only able to measure fasting S-Pi
concentrations. Thus, in future research, more resources should be
directed to more extensive S-Pi assessments, not only relying on fasting
concentrations. Also measuring urine Pi excretion would be valuable
(Karp et al. 2007, Morimoto et al. 2014); however, 24-h urine collection
is laborous to carry out and can only be used for subjects with normal
renal function.
The main factors involved in P metabolism, namely FGF23, PTH, and
calcitriol, have been found to be independently adversely associated with
cardiovascular health (Uribarri and Calvo 2014). Although dietary P load
has been shown to increase FGF23 concentration during a long exposure
(Block et al. 2013), one failed to find any association between P-FGF23
concentration and dietary P intake in the current study, probably due to
the cross-sectional study design. Also the analysis of the C-terminal
fraction of FGF23 may explain the lack of the correlations in the current
study; as mentioned earlier, intact FGF23 has been found to respond
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better to dietary P load (Burnett et al. 2006). FGF23 has been speculated
to  participate  in  the  effects  of  P  on  CVD,  but  the  mechanisms  are
hypothetical and mainly unknown (Kendrick et al. 2011). High FGF23
has been associated with CVD risk factors (Gutiérrez et al. 2011) and
CVD itself (Dalal et al. 2011) but results of studies are discordant (Taylor
et al. 2011, Schoppet et al. 2012), and to date, no studies have focused on
FGF23 and IMT in the general population.
PTH concentrations increase acutely after dietary P load (Vervloet et al.
2011, Block et al. 2013). However, in the present study dietary P
variables were associated with IMT, but no correlation between serum
iPTH concentrations and IMT was observed (data not shown). A meta-
analysis of 15 prospective studies showed that higher PTH concentrations
were associated with increased risk of CVD events (van Ballegooijen et al.
2013). However, with regard total CVD events (10 studies included in the
analysis) only three of the studies showed a positive association between
PTH and CVD, the rest  reporting no association (van Ballegooijen et  al.
2013). In the present study, S-Pi, FGF23 and iPTH analyses concerning
IMT were not adjusted for potential covariates because they were not
main parameters of the study but the data will be further analyzed in other
manuscripts. However, the results should be interpreted with caution:
more investigation on these surrogate markers of P intake and
cardiovascular health are warranted.
6.2.4. Conclusions about dietary phosphorus as a potential
cardiovascular risk factor
The results show significant linear trends in the associations among P
density of the diet, FAP intake, and carotid IMT in a healthy, middle-aged
Caucasian population. Based on these results, high dietary P intake should
be further investigated due to its potential association with CVD risk
factors in the general population, not only in renal patients. Furthermore,
prospective, or even better, long-term intervention studies are required to
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evaluate the possible impact of dietary P burden on risk of CVD. Also the
regulators of P metabolism should be taken into account.
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6.3. Strengths and limitations of the studies
6.3.1. Food studies (Studies I and II)
In  the  method  for  DP  analysis,  the  processing  of  the  food  in  the
alimentary tract was mimicked, but this in vitro method do not take into
account the interaction between the alimentary tract and food or
components of food (Sandberg 2005), and therefore the results on DP
need further validation with an in vivo method. For example, the transit
time in the alimentary tract depends on the content of the meal, and
absorption capability in the different parts of the alimentary tract varies.
Moreover, the produced alimentary enzymes differ in contents and
concentrations depending on the composition of ingested food, neither
was the circulation present in this method. This naturally causes
uncertainty in extrapolating the in vitro results to in vivo circumstances.
The  ICP-MS and ICP-OES methods  for  total  P  analysis  are  reliable  and
well validated (PerkinElmerSciex Instruments 2001). The differences in
results for P contents in breads between Studies I and II can be partly
explained by sampling differences. In Study I, the focus was on the
effects of processing on P contents in particular foodstuffs, while in Study
II the sampling was ensured to be representative of the most popular
trademarks in each food category, and the food consumption data
originated from a population study in Finland. Nevertheless, because
Study I  was  a  methodological  study,  the  samples  were  not  chosen  to  be
generally representative; the main aims were to develop a new analysis
method and to examine the effect of baking processes on the DP contents.
The percentage of DP from TP was in some foodstuffs more than 100%,
which may be explained by the variance in the uncertainty of the method,
at least at low P concentrations. Measurement accuracy was, however,
improved by extraction of fat from high-fat-containing foodstuffs. In the
present studies, only plant-based foodstuffs were analyzed but the same
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method has been used for analysis of animal-based foodstuffs in the study
by Karp et al. (2012).
6.3.2. Human study (Study III)
Here, a large variety of biomarkers were analyzed and extensive
background data were available. Further, the study subjects were
homogeneous in age and the females were in specified state of menopause
(premenopausal). The potential effects of impaired kidney functions were
taken into account by excluding persons with eGFR<60 ml/min. In large
studies where the main focus is not nutritional, food intake data may have
been collected less accurately than in our study. Nevertheless, among the
study subjects Ca intake was high, and serum 25-hydroxy vitamin D
status was fairly satisfactory, both of which interact with P metabolism
and may hide adverse effects of high P intake. One limitation of the study
is its cross-sectional design, which prevents an evaluation of causality.
The number of males (176 vs. 400 expected) may have been too small to
show statistically significant results.
One problem with dietary intake calculation programs is that the analyzed
TP content, for example in meat products, can be twice as high as that
based on food composition databases due to a lack of analyzed data for
FAP content (Calvo et al. 2014). Here, the food intake (except FAP intake)
was assessed only with self-reported food records (3 days); however, the
records were checked by researchers, in an attempt to improve the quality
of the data. In addition, 400 new recipes were introduced to the nutrient
calculation program to ensure more accurate assessment of P intake and
other nutrients. However, the database used is based on Fineli®, which
has  limited  information  on  FAPs.  Thus,  it  is  important  to  have  data  on
consumption of FAP-containing foodstuffs measured by a validated FFQ.
Also different processing methods for foods actually consumed and the
subjects’ former diets may have affected the associations of dietary P with
other measured parameters. Food records and FFQs were not repeated,
and  reveal  the  only  current  dietary  intake  and  it  is  difficult  to  know
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whether the dietary intake method used is indicative of the usual diet. The
method by which FAP intake is calculated can also be criticized; in the
present study FAP intakes were not able to calculate precisely, and only
FAP-containing meat products, processed cheeses, and cola beverages
were included in the FAP intake calculations, but, however, information
on exact amounts of FAPs in foodstuffs was not available.
IMT measurement by sonography is a reproducible, rapid, inexpensive,
and radiation-free technique to evaluate the condition of arteries and risk
of CVD (Mookadam et al. 2010, O’Leary and Bots 2010). Here, the
population was middle-aged, and the age group was chosen based on
literature suggesting that some changes in vessels probably already occur
by this time. However, it was not able to distinguish between carotid
intima and media layers of the vessels, thus, one cannot be sure whether
this calcification occurs in the intima, media, or both. That leaves the
effect of the P separately on intima and media unknown. More
assessments, e.g. measurement of endothelial function of the vessels,
would have provided valuable additional information.
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7. Conclusions and future perspectives
This thesis aimed to provide new insights into the potential health risks
related to P intake in Finland by producing new infomation on the
bioavailability of P from foodstuffs commonly used in Finland in terms of
in vitro digestible P. Due to increased consumption of processed meals, it
is important to pay attention to the sources of bioavailable P. Furthermore,
the study yielded population-based data on the associations of dietary P,
especially food additive P, and vascular calcification in Finland.
Cardiovascular diseases are common causes of death in Finland, and the
information about the potential detrimental role of dietary P in these
diseases is highly important.
Specific findings of the studies were as follows:
Food studies (Studies I and II): Information on in vitro digestible P
contents in differently processed cereals, as well different plant-based
foodstuffs was attained. Also a new reliable analysis method was tested.
Despite high total P content, cereals, legumes and seeds may be relatively
poor sources of bioavailable P, even though processing of the cereals
increases DP contents. Results support previous understanding of the
effective absorption of P from additives. The use of food additive
phosphate-containing products may substantially increase the intake of
highly bioavailable P. The results of in vitro digestible P should, however,
be confirmed with an in vivo method.
Human study (Study III): High P density of the diet i.e. total dietary P
intake relative to energy intake, and high food additive phoshate intake
were associated with carotid intima-media thickness in healthy middle-
aged Finnish adults. However, due to the cross-sectional design, causal
effects cannot be shown. Based on these results, high dietary P should be
further investigated for its potential association with cardiovascular
disease risk factors in the general population, not only in renal patients.
The relationship between high P intake and vascular calcification requires
also further elucidation.
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In conclusion, the present results highlight the importance of the source of
P when analyzing P intake and P burden in a population. Food additive
phosphate-containing foodstuffs have higher contents of in vitro
digestible P, and also processing increases the digestible P contents. Both
intervention and follow-up studies are warranted on different populations
before final conclusions about the harmfulness of high P intake on
cardiovascular health in the general population can be drawn. Data on use
of food additive phosphates in the food industry and updated information
on P contents in foodstuffs are also needed.
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APPENDIX
Table 1 . Wet digestion program for total and in vitro digestible phosphorus analysis in Study I.
               Total phosphorus          Digestible phosphorus
Phase Temperature (˚C) Time (h) Temperature (˚C) Time (h)
1 70 3 70 6
2 90 0,5 90 1,5
3 110 0,5 110 1,5
4 130 3,5 130 6
5 145 0,5 - -
6 160 0,5 - -
Table 2. Information on home-baked samples in Study I. Baking temperature was 200˚C, except
for barley porridge, which was baked at 120˚C.
Sample Ingredients Leavening
time (h)
Baking time
(min)
Whole-grain rye bread Whole-grain rye flour (ash content 1.6%), water,
rye sourdough, NaCl
23 60
Barley porridge Barley grits, water, salt - 180
NaCl = sodium chloride.
Wheat bread White wheat bread flour (ash content 0.6%),
water, yeast, NaCl
0.75 25
Sourdough wheat bread White wheat bread flour (ash content 0.6%),
water, yeast, rye sourdough, NaCl
20 25
Table 3. The absolute amounts of in vitro digestible phosphorus (DP) and total phosphorus (TP) contents
within measurement uncertainty of the analyzed products.
 TP (mg/100g)  DP (mg/100g)
Mean ± Mean ±
measurement uncertainty measurement uncertainty
Rye flour 300.8±19.2 135.0±10.0
Rye sourdough 160.7±10.2 131.6±9.7
Bakery whole rye bread 203.8±13.0 145.4±10.8
Bakery rye bread containing wheat and potato 186.6±11.9 128.7±9.5
Home-baked rye bread 171.9±11.0 134.4±10.0
Wheat flour 116.7±7.4 50.2±3.7
Unsoured wheat dough 76.9±4.9 42.8±3.2
Unsoured wheat bread 82.2±5.2 38.1±2.8
Soured wheat dough 79.4±5.1 47.7±3.5
Soured wheat bread 81.5±5.2 39.0±2.9
Bakery wheat bread 82.5±5.3 42.3±3.1
Barley grit 153.7±9.8 43.8±3.2
Barley porridge 29.0±1.9 20.1±1.5
